牛黄解毒片的遗传毒性研究及其方药配伍减毒作用初探
|
摘要
牛黄解毒片是中医临床清热解毒的经典方剂,用于治疗火热内盛,咽喉肿痛,牙龈肿痛,口舌生疮及目赤肿痛等症。为评价牛黄解毒片的安全性,本研究采用Ames试验、染色体畸变分析、单细胞凝胶电泳试验(SCGE).微核试验等方法,探讨了牛黄解毒片在体内、外实验条件下,有无潜在的遗传毒性作用；此外,配伍是最具中医特色的减毒方法和技术之一,为探讨牛黄解毒片配伍对雄黄是否具有减毒作用,本研究在已有研究基础上,设立牛黄解毒片全方及其不同拆方组,通过可溶性砷盐含量、砷在机体组织的分布、病理损伤、氧化损伤、遗传损伤、细胞凋亡等指标的检测,拟初步探讨牛黄解毒片方药配伍对雄黄有无减毒作用及其可能机制。
1牛黄解毒片的遗传毒性研究
1.1牛黄解毒片遗传毒性的体外实验研究
1.1.1牛黄解毒片对鼠伤寒沙门氏菌菌株的回复突变作用采用平皿掺入法,按照Maron DM和Ames BN推荐程序,根据预试验结果,以5mg.IIII-1为最高剂量,下设1.5、0.5、0.15、0.05mg.IIII-1四个剂量组和阴、阳性对照组开展实验。结果表明,牛黄解毒片水溶液在试验剂量为0.05mg.IIII-1至5mg.IIII-1,在加与不加S9混合液两种情况下,各剂量组和阴性对照组比较,差异均无统计学意义,且各菌株的回复菌落数均未超过阴性对照组2倍,也未呈现一定剂量-反应关系。
1.1.2牛黄解毒片对CHL细胞的染色体畸变作用采用细胞计数法测出牛黄解毒片水溶液对CHL细胞的半数生长抑制浓度(IC50)约为54μg.ml-1,以此浓度为高剂量组,采用倍比稀释法,设立中、低剂量组(分别为27和13.5μg.ml-1)进行染色体畸变实验。结果表明,牛黄解毒片在接触24h时和在加入活化系统S9接触6h时,高、中、低三个剂量组的染色体畸变率均小于5%,为阴性反应；而牛黄解毒片在接触48h时,中剂量组的畸变率为8.5%,大于5%为可疑阳性反应,高、低二个剂量组畸变率小于5%,为阴性反应。
1.1.3牛黄解毒片对CHL细胞的DNA损伤作用应用单细胞凝胶电泳实验(SCGE)检测了牛黄解毒片对CHL细胞DNA链的断裂作用,结果显示,CHL细胞接触牛黄解毒片水溶液48h后,中、低剂量组与阴性对照组比较,差异无显著性；而高剂量组与阴性对照组比较,差异有显著性(P<0.05),表明本实验条件下,牛黄解毒片水溶液高浓度时会引起体外培养CHL细胞DNA的损伤。
1.2牛黄解毒片遗传毒性的整体动物实验研究
1.2.1牛黄解毒片对小鼠体细胞染色体完整性与分离改变的影响采用经口给药,进行小鼠骨髓嗜多染红细胞微核试验。设立三个剂量组(3345、1670、835mg.kg-1)和一个阳性对照组(环磷酰胺,按40mg.kg-1腹腔注射)及一个阴性对照组,按两种方案(“0”和“24”小时两次给药和连续6周给药)检测牛黄解毒片对染色体的影响。结果表明,“0”与“24”小时两次给药,各剂量组与阴性对照组比较均无显著性差异(P>0.05),提示本方案下,牛黄解毒片对小鼠体细胞染色体的完整性和染色体分离无明显影响。但给药6w后,在剂量为1672mg.kg-1及3340mg.kg-1时,小鼠骨髓嗜多染红细胞微核率与阴性对照组比较差异有统计学意义(P<0.05),且各个剂量组之间存在明显剂量反应关系(r=0.999,P=0.023),提示给药6w,牛黄解毒片可引起小鼠骨髓嗜多染红细胞微核率增加。1.2.2牛黄解毒片对小鼠生殖细胞遗传损伤的影响采用经口给药,进行小鼠精子畸形试验。设立三个剂量组(3345、1670、835mg.kg-1)和一个阳性对照组(环磷酰胺,按40mg.kg-1腹腔注射)及一个阴性对照组,按两种方案(5d给药和连续6周给药)检测牛黄解毒片对小鼠生殖细胞的遗传损伤作用。结果显示,两种给药方案,各剂量组与阴性对照组比较均无显著性差异(P>0.05),表明本实验条件下,牛黄解毒片对小鼠生殖细胞无明显遗传损伤作用。
1.2.3牛黄解毒片对小鼠主要组织细胞DNA链断裂作用的检测采用单细胞凝胶电泳技术(SCGE),检测不同给药剂量(3345、1670、835mg.kg-1)及不同给药时段(1w、2w、3w、4w和5w)的牛黄解毒片对小鼠外周血细胞DNA的断裂情况,并于末次给药后检测牛黄解毒片对肺、肝、肾、脾细胞DNA的断裂作用。结果显示,给药2w、3w时,高剂量组即可引起外周血淋巴细胞DNA链发生断裂,给药4w、5w时,高、中、低三个剂量均可引起外周血淋巴细胞DNA发生断裂作用；牛黄解毒片经口给药6w后,高、中剂量组肝、肺细胞及高剂量组的肾细胞的DNA损伤与阴性对照组比较,差异有统计学意义,表明牛黄解毒片经口给药6w可能会致肝、肺及肾细胞DNA损伤作用。
初步结论：以上研究结果表明,在体内、外实验条件下,牛黄解毒片无明显遗传毒性作用,但随着给药剂量及给药时间的延长,牛黄解毒片可能具有一定蓄积性的遗传毒性；
2牛黄解毒片配伍减低雄黄砷毒性作用初探
2.1牛黄解毒片配伍对雄黄可溶性砷含量的影响采用原子荧光法测定牛黄解毒片全方及其不同拆方组中的可溶性砷盐的含量。结果显示,不管是人工胃液还是人工肠液处理,牛黄解毒片全方配伍后,均可明显降低雄黄中可溶性砷含量,并且,牛黄解毒片去甘草、黄芩、大黄后,其可溶性砷又明显升高,这表明牛黄解毒片全方配伍对雄黄可能有减毒作用,而甘草、黄芩、大黄三味中药可能是发挥减毒作用的药物。
2.2牛黄解毒片配伍减低雄黄砷毒性的动物实验研究
2.2.1牛黄解毒片配伍对雄黄中砷吸收分布的影响采用原子荧光光谱法测定并分析牛黄解毒片全方配伍对雄黄中砷在机体内的吸收与分布的影响。结果显示,给药9周后,雄黄组的肝、肾、脾、心、肺组织砷浓度均高于阴性对照组,差异有统计学意义(P<0.05),进一步证实雄黄中砷在机体内可被吸收并分布。各组与全方组比较,雄黄组的肝、肾、脾、心、肺组织砷浓度均明显高于全方组(P<0.05),而全方去甘草、黄芩、大黄组的肝、脾、心组织砷浓度明显高于全方组(P<0.05),这提示牛黄解毒片全方配伍后可减少雄黄中砷在机体内的吸收与分布,并且去除甘草、黄芩、大黄三味中药后,部分机体组织对雄黄中砷的吸收可能增加。
2.2.2牛黄解毒片配伍对雄黄遗传毒性的影响采用彗星技术、微核试验等测定牛黄解毒片全方及其拆方对遗传损伤的影响。研究显示,与阴性对照组比较,单味雄黄组小鼠血细胞DNA损伤、骨髓嗜多染红细胞微核形成率增加及精子畸变率均升高(P<0.05)；与雄黄组比较,牛黄解毒片全方组小鼠血细胞DNA损伤与微核形成率明显降低(P<0.05),精子畸变率无明显变化；全方去甘草、黄芩、大黄后,与全方组比较,DNA损伤作用明显增强,但微核形成率、精子畸形率未见明显改变。表明牛黄解毒片配伍可能会减低雄黄的遗传损伤作用,但具体药味尚不能明确与甘草、黄芩、大黄有关。
2.2.3牛黄解毒片配伍对雄黄肝肾毒性的影响采用病理组织学观察,分析牛黄解毒片配伍对雄黄肝肾毒性的影响。结果显示,雄黄组肝组织细胞显著水肿,局部有坏死；而肾脏组织出现局部肾小管细胞重度水肿；牛黄解毒片全方组及牛黄解毒片去雄黄组的肝肾组织未见明显异常,表明牛黄解毒片配伍能减低雄黄组肝肾毒性。
2.2.4牛黄解毒片配伍对肝肾组织氧化损伤的影响采用生物化学方法,测定各组肝肾组织脂质过氧化物MDA含量、抗氧化酶SOD和GSH-px的活力。结果显示,与阴性对照组及与牛黄解毒片全方组比较,雄黄组的肝、肾组织中GSH-px酶、SOD活力活力均显著下降(P<0.05),而MDA均明显升高(P<0.05),这表明雄黄的肝肾毒性可能与氧化损伤作用有关,而牛黄解毒片配伍减低雄黄肝肾毒性可能与抗氧化损伤有关。全方去甘草、黄芩、大黄组与全方组比较未见有明显差异,提示甘草、黄芩、大黄三味药在方中抗氧化尚不能明确。
2.2.5牛黄解毒片配伍对细胞凋亡的影响采用TUNNEL、免疫组化法测定牛黄解毒片配伍对肝细胞凋亡和凋亡相关分子表达的影响。结果显示,与阴性对照组比较,雄黄组的TUNEL阳性细胞数明显增加,Bax表达平均光密度明显增加,Bcl2表达平均光密度明显减少(P<0.05)：牛黄解毒片配伍后,TUNEL阳性细胞数较雄黄组明显减少,Bax表达平均光密度明显减少,Bcl2表达平均光密度明显增多(P<0.05)。这表明诱导肝细胞凋亡可能是雄黄引起肝损伤的可能机制；牛黄解毒片配伍对雄黄的诱导凋亡作用产生了抑制,抑制过程可能是通过促进Bcl2表达而阻碍bax表达来实现的。全方去甘草、黄芩、大黄组凋亡细胞数较全方组增加,Bax表达明显增加,但Bcl2表达无明显变化。
初步结论：牛黄解毒片配伍可以减低雄黄的砷毒性(肝肾毒性、遗传毒性),甘草、黄芩及大黄在方中可能是发挥减毒作用的重要药味,机制可能与减少可溶性砷的吸收与分布、抗氧化、抗凋亡有关。
The Niuhuang jiedu tablet is a representative of Qingrejiedu prescription in TCM, usually using for filled hot, sore throat, sore gums, tongue festered, red and swelling eyes and etc. For the evaluation Niuhuangjiedu security, the Ames test, chromosome aberration analysis, single cell gel electrophoresis assay (SCGE) and micronucleus tests were used, respectively, to explore the potential genotoxic effects of Niuhuang jiedu tablet. In addition, compatibility detoxification is one of the most characteristic methods and techniques for TCM, to explore whether the compatibility for Niuhuang jiedu tablet could reduce the toxicity of realgar and what is its possible mechanisms, different groups about Niuhuangjiedu tablet and its disassembled presciption were arranged, and soluble arsenic, arsenic in the body tissue distribution, pathological damage, oxidative damage, genetic damage, apoptosis etal, were detected.
1Genetoxicity evaluation for Niuhuang jiedu tablet
1.1Genetoxicity studies of Niuhuang jiedu tablet in in vitro bioassays
1.1.1Effects of Niuhuangjiedu tablet on gene reverse mutation Plate incorporation assay was adopted, in accordance with Maron, DM and Ames BN recommended procedures. Based on the pre-test results,5mg/dish was arranged as the highest dose group, then,1.5,0.5,0.15,0.05mg/dish, negtive and positive control groups were also arranged to carry out the experiment. The results showed no difference on gene reverse mutation of Trphoid Salmonella Strains, from0.05mg/dish to5mg/dish, both with and without S9mixture, and replies colonies number of various strains did not exceed2times the negative control group, and dose-response relationship was not showed.
1.1.2Chromosomal aberrations effect of Niuhuangjiedu tablet on CHL cells The IC50of Niuhuangjiedu tablet was determined as54μg.ml-1, by cell counting method. Dose range for chromosome aberration test was1.0,1/2,and1/4IC50values, i.e,54,27.13.5μg.ml-1respectively. The results showed that chromosome aberration rate of all dose group were less than5%, at24hrs exposure, and at9hrs exposure with the activation system S9, which is a negative response, chromosome aberration rate of the middle dose group was8.5%, which is greater than5%, and is a suspicious positive, at48hrs exposure, but chromosome aberration rate of high and low dose group is less than5%.
1.1.3DNA damage effect of Niuhuangjiedu tablet on CHL cells The DNA strand break effect of Niuhuangjiedu tablet on CHL cells was tested by SCGE. Dose range was also1.0,1/2,and1/4IC50values, i.e,54,27.13.5μg.ml-1respectively. The results showed DNA damage rised at the54μg.ml-1dose group after48hrs exposure in comparation with the negative control group, and the difference was significant (P<0.05), but there were no difference was found at medium and low dose group, which means Niuhuangjiedu tablet could induce DNA strand break of CHL cells at high dose.
1.2Genetoxicity studies of the Niuhuangjiedu tablet in in vivo assays
1.2.1The influence of Niuhuangjiedu tablet on chromosome integrity and separation changes Bone marrow PCE cell micronucleus test in mice exposed Niuhuangjiedu tablet through oral delivery with three dose groups (3345,1670,835mg.kg-1) was carried out, and two administering drugs regimens ("0" and "24" hrs administration at twice and6weeks continuous administration) were arranged. The results showed that the "0" and "24" hrs administration at twice, no significant difference (P>0.05)was found at each dose group,which suggested that under this regimen, the Niuhuangjiedu tablet had no influence on mice chromosome integrity and chromosome segregation. But under6weeks administration regimen, micronucleus rate at dose of1672mg.kg-1and3345mg.kg-1was found higher than that of negative control group (P <0.05), and the obvious dose-response relationship (r=0.999, P=0.023)was found, which means Niuhuangjiedu tablet could increase the mouse bone marrow cells micronucleus rate under long time administration.
1.2.2Sperm abnormality test in mice exposed to Niuhuangjiedu tablet Sperm abnormality test in mice exposed to Niuhuangjiedu tablet was carried out with three dose groups (3345,1670,835mg.kg-1), and the two administering drugs regimens (5d days administration and6weeks administration) were arranged. The results showed each dose group and the negative control group showed no significant difference (P>0.05) under two regimens, which means Niuhuangjiedu tablet has no significant genetic damage effect on germ cells in mice under this experimental conditions.
1.2.3DNA strand break of main tissues and organs cells in mice exposed to Niuhuangjiedu tablet SCGE technique was used to detect DNA strand breaks of peripheral blood cell in mice exposed to Niuhuangjiedu tablet, at different dose (3345,1670,835mg.kg-1) for different administration times (1w,2w,3w,4w and5w), and after the last administration, DNA strand breaks of mice lung, liver, kidney, spleen cell were also detected. The results showed that the DNA of peripheral blood lymphocytes began to perform strand breaks at administration2w or3w with high dose, and then significant DNA strand breaks were detected at all dose groups after administration4w or5w. Significant DNA strand breaks were also detected in cells of liver, lung cells at high and medium dose groups, and in renal cell at high dose groups, when compared with negtive control group, which indicates that Niuhuangjiedu tablet may induce DNA damage of liver, lung and renal cell after administration6w and through oral delivery.
Preliminary Conclusion:Niuhuangjiedu tablet had no obvious genetoxicity in in vitro and vivo experimental conditions, but with the increase of administration dose and the extension of administration time, which may have cumulative genetoxicity.
2The preniminary exploration on Niuhuangjiedu compatibility reducing realgar arsenic toxicity
2.1Determination of Soluble Arsenic in NiuhuangJiedu Tablet and its disassembled presciption Different groups about NiuhuangJiedu Tablet and its disassembled presciption were arranged, treated with artificial gastric juice or artificial intestine juice, then Atom Fluorescence Spectrophotometry(AFS) was used to detected the content of soluble Arsenic in the different groups samples. The result showed the content of soluble Arsenic in the whole presciption of NiuhuangJiedu Tablet was significant lower than that in the single relgar (P<0.01), the content of soluble Arsenic in the whole presciption with Gancao,Hangqin,Dahuang excluded was significant higher than that in the whole presciption of NiuhuangJiedu Tablet (P<0.01),which suggested the compatibility for Niuhuangjiedu Tablet could reduce the toxicity of realgar,and Gancao,Hangqin and Dahuang may be the possible herbal medicines that play the role of reducing toxicity.
2.2Animal experiment studies on Niuhuangjiedu Tablet compatibility reducing realgar arsenic toxicity
2.2.1The influence of Niuhuangjiedu tablet compatibility on the absorption and distribution of arsenic in realgar The AFS was used to detect and analye the influence of Niuhuangjiedu tablet on the absorption and distribution of arsenic in realgar. The results showed arsenic content in liver, kidney, spleen, heart and lung tissue in the single realgar was significantly higher than that of negtive group after administration9W (P<0.05), which confirmed that the arsenic in realgar could be absorpted and distributed in bodies. Compared with the whole presciption of NiuhuangJiedu Tablet, arsenic content in liver, kidney, spleen, heart and lung tissue in realgar was significantly higher (P<0.05), and arsenic content in liver, spleen, heart tissue in the whole presciption with Gancao,Hangqin,Dahuang excluded was also significant higher (P<0.05) which suggested the compatibility for Niuhuangjiedu Tablet could reduce the absorption and distribution of arsenic in realgar, and the absorption and distribution of arsenic in realgar may increase if Gancao, Hangqin.Dahuang in whole presciption of NiuhuangJiedu Tablet are excluded.
2.2.2The influence of Niuhuangjiedu tablet compatibility on the oxidative stress The lipid peroxide product MDA and antioxidant enzymes SOD and GSH-px were determined to explore the influence of Niuhuangjiedu tablet compatibility on the oxidative damage. The results showed GSH-px enzyme activity in the liver, kidney, lung, heart tissue and SOD enzyme activity in liver kidney, spleen tissue decreased significantly (P<0.05).and MDA content in liver, kidney, heart tissue increased significantly (P<0.05),when single realgar compared with the negtive group. However, the GSH-px and SOD enzyme activity and MDA content in the whole presciption and in the whole presciption with Gancao, Hangqin, Dahuang excluded showed no significant change (P>0.05), which indicates that the realgar could cause oxidative damage, and Niuhuangjiedu compatibility could reduce oxidative damage caused by realgar, but which are the main herbs that play the role of antioxidative damage may not be determined.
2.2.3The influence of Niuhuangjiedu tablet compatibility on genetic damage Comet technology, the micronucleus test, etc were used to determined the influence of Niuhuangjiedu tablet compatibility on genetic damage. The results showed the DNA damage in peripheral blood cell, micronucle formation rate in bone marrow PCE cell, and the sperm abnormality rate in single realgar increased signiffcantly (P<0.05),when compared with the negative group. DNA damage, micronucleus formation rate decreased signiffcantly (P<0.05), sperm abnormality rate had no signiffcant difference in the whole presciptio of Niuhuangjiedu tablet in comparation with single realgar; DNA damage, micronucle formation rate and sperm abnormality rate in the whole presciption with Gancao,Hangqin,Dahuang excluded showed no significant change. These results indicates that the Niuhuangjiedu compatibility could reduce the genetic injury of realgar, but the specific herbs that play role of antigenetic damage was not yet determined.
2.2.4The influence of Niuhuangjiedu tablet compatibility on liver and kidney toxicity The pathological and hisological observation was used to analye the influence of Niuhuangjiedu tablet compatibility on liver and kidney toxicity of realgar. The results showed that liver tissue in the realgar was significantly edema, local necrosis; and local renal tubular cells in kidney tissues in the realgar was severe edema; The liver and kidney tissues showed no abnormal changes except local edema in the whole presciption of NiuhuangJiedu Tablet and the whole presciption with realgar excluded, which suggested Niuhuangjiedu tablet compatibility may could reduce the liver and kidney toxicity of realgar. The liver tissue showed mild edema and kidney tubular epithelial cells showed moderate edema in the whole presciption with Gancao, Hangqin, Dahuang excluded, which indicates the liver and kidney toxicity may be enhanced with Gancao, Hangqin, Dahuang removed from the whole presciption of NiuhuangJiedu.
2.2.5The influence of Niuhuangjiedu tablet compatibility on liver apoptosis The TUNEL and immunohistochemical methods were used to determine the influence of Niuhuangjiedu tablet compatibility on liver apoptosis and apoptosis related molecules expression. Results showed the TUNEL positive cell numbers and mean density of Bax expression increased significantly, but mean density of Bcl2expression reduced significantly, when realgar group compared with negative group (P<0.05). However, TUNEL-positive cell numbers and mean density of Bax expression decreased significantly, and mean density of Bcl2expression increased significantly, when the whole presciption compared with the single realgar (P<0.05), indicates the Niuhuangjiedu compatibility may inhibit liver apoptosis that realgar induced, and such inhibition may be achieved by promoting bcl2expression and inhibiting bax expression. The whole presciption with Gancao, Hangqin, Dahuang excluded in compared with the whole presciption, the TUNEL positive cell numbers and mean density of Bax expression increased significantly, but mean density of Bcl2expression had no apparent changes, which indicated Gancao, Hangqin. Dahuang in the whole presciption may reduce the liver toxicity of realgar by antiapoptosis.
Preliminary Conclusion:The compatibility of Niuhuangjiedu tablet may reduce the asenic toxicity of realgar, and reducing absorption and distribution of soluble arsenic, antioxidative damage, antiapoptosis, and et al maybe the possible mechanisms. The specific herbs that reduced asenic toxicity of realgar were not yet determined in this study, which needs further research.
1牛黄解毒片的遗传毒性研究
1.1牛黄解毒片遗传毒性的体外实验研究
1.1.1牛黄解毒片对鼠伤寒沙门氏菌菌株的回复突变作用采用平皿掺入法,按照Maron DM和Ames BN推荐程序,根据预试验结果,以5mg.IIII-1为最高剂量,下设1.5、0.5、0.15、0.05mg.IIII-1四个剂量组和阴、阳性对照组开展实验。结果表明,牛黄解毒片水溶液在试验剂量为0.05mg.IIII-1至5mg.IIII-1,在加与不加S9混合液两种情况下,各剂量组和阴性对照组比较,差异均无统计学意义,且各菌株的回复菌落数均未超过阴性对照组2倍,也未呈现一定剂量-反应关系。
1.1.2牛黄解毒片对CHL细胞的染色体畸变作用采用细胞计数法测出牛黄解毒片水溶液对CHL细胞的半数生长抑制浓度(IC50)约为54μg.ml-1,以此浓度为高剂量组,采用倍比稀释法,设立中、低剂量组(分别为27和13.5μg.ml-1)进行染色体畸变实验。结果表明,牛黄解毒片在接触24h时和在加入活化系统S9接触6h时,高、中、低三个剂量组的染色体畸变率均小于5%,为阴性反应；而牛黄解毒片在接触48h时,中剂量组的畸变率为8.5%,大于5%为可疑阳性反应,高、低二个剂量组畸变率小于5%,为阴性反应。
1.1.3牛黄解毒片对CHL细胞的DNA损伤作用应用单细胞凝胶电泳实验(SCGE)检测了牛黄解毒片对CHL细胞DNA链的断裂作用,结果显示,CHL细胞接触牛黄解毒片水溶液48h后,中、低剂量组与阴性对照组比较,差异无显著性；而高剂量组与阴性对照组比较,差异有显著性(P<0.05),表明本实验条件下,牛黄解毒片水溶液高浓度时会引起体外培养CHL细胞DNA的损伤。
1.2牛黄解毒片遗传毒性的整体动物实验研究
1.2.1牛黄解毒片对小鼠体细胞染色体完整性与分离改变的影响采用经口给药,进行小鼠骨髓嗜多染红细胞微核试验。设立三个剂量组(3345、1670、835mg.kg-1)和一个阳性对照组(环磷酰胺,按40mg.kg-1腹腔注射)及一个阴性对照组,按两种方案(“0”和“24”小时两次给药和连续6周给药)检测牛黄解毒片对染色体的影响。结果表明,“0”与“24”小时两次给药,各剂量组与阴性对照组比较均无显著性差异(P>0.05),提示本方案下,牛黄解毒片对小鼠体细胞染色体的完整性和染色体分离无明显影响。但给药6w后,在剂量为1672mg.kg-1及3340mg.kg-1时,小鼠骨髓嗜多染红细胞微核率与阴性对照组比较差异有统计学意义(P<0.05),且各个剂量组之间存在明显剂量反应关系(r=0.999,P=0.023),提示给药6w,牛黄解毒片可引起小鼠骨髓嗜多染红细胞微核率增加。1.2.2牛黄解毒片对小鼠生殖细胞遗传损伤的影响采用经口给药,进行小鼠精子畸形试验。设立三个剂量组(3345、1670、835mg.kg-1)和一个阳性对照组(环磷酰胺,按40mg.kg-1腹腔注射)及一个阴性对照组,按两种方案(5d给药和连续6周给药)检测牛黄解毒片对小鼠生殖细胞的遗传损伤作用。结果显示,两种给药方案,各剂量组与阴性对照组比较均无显著性差异(P>0.05),表明本实验条件下,牛黄解毒片对小鼠生殖细胞无明显遗传损伤作用。
1.2.3牛黄解毒片对小鼠主要组织细胞DNA链断裂作用的检测采用单细胞凝胶电泳技术(SCGE),检测不同给药剂量(3345、1670、835mg.kg-1)及不同给药时段(1w、2w、3w、4w和5w)的牛黄解毒片对小鼠外周血细胞DNA的断裂情况,并于末次给药后检测牛黄解毒片对肺、肝、肾、脾细胞DNA的断裂作用。结果显示,给药2w、3w时,高剂量组即可引起外周血淋巴细胞DNA链发生断裂,给药4w、5w时,高、中、低三个剂量均可引起外周血淋巴细胞DNA发生断裂作用；牛黄解毒片经口给药6w后,高、中剂量组肝、肺细胞及高剂量组的肾细胞的DNA损伤与阴性对照组比较,差异有统计学意义,表明牛黄解毒片经口给药6w可能会致肝、肺及肾细胞DNA损伤作用。
初步结论：以上研究结果表明,在体内、外实验条件下,牛黄解毒片无明显遗传毒性作用,但随着给药剂量及给药时间的延长,牛黄解毒片可能具有一定蓄积性的遗传毒性；
2牛黄解毒片配伍减低雄黄砷毒性作用初探
2.1牛黄解毒片配伍对雄黄可溶性砷含量的影响采用原子荧光法测定牛黄解毒片全方及其不同拆方组中的可溶性砷盐的含量。结果显示,不管是人工胃液还是人工肠液处理,牛黄解毒片全方配伍后,均可明显降低雄黄中可溶性砷含量,并且,牛黄解毒片去甘草、黄芩、大黄后,其可溶性砷又明显升高,这表明牛黄解毒片全方配伍对雄黄可能有减毒作用,而甘草、黄芩、大黄三味中药可能是发挥减毒作用的药物。
2.2牛黄解毒片配伍减低雄黄砷毒性的动物实验研究
2.2.1牛黄解毒片配伍对雄黄中砷吸收分布的影响采用原子荧光光谱法测定并分析牛黄解毒片全方配伍对雄黄中砷在机体内的吸收与分布的影响。结果显示,给药9周后,雄黄组的肝、肾、脾、心、肺组织砷浓度均高于阴性对照组,差异有统计学意义(P<0.05),进一步证实雄黄中砷在机体内可被吸收并分布。各组与全方组比较,雄黄组的肝、肾、脾、心、肺组织砷浓度均明显高于全方组(P<0.05),而全方去甘草、黄芩、大黄组的肝、脾、心组织砷浓度明显高于全方组(P<0.05),这提示牛黄解毒片全方配伍后可减少雄黄中砷在机体内的吸收与分布,并且去除甘草、黄芩、大黄三味中药后,部分机体组织对雄黄中砷的吸收可能增加。
2.2.2牛黄解毒片配伍对雄黄遗传毒性的影响采用彗星技术、微核试验等测定牛黄解毒片全方及其拆方对遗传损伤的影响。研究显示,与阴性对照组比较,单味雄黄组小鼠血细胞DNA损伤、骨髓嗜多染红细胞微核形成率增加及精子畸变率均升高(P<0.05)；与雄黄组比较,牛黄解毒片全方组小鼠血细胞DNA损伤与微核形成率明显降低(P<0.05),精子畸变率无明显变化；全方去甘草、黄芩、大黄后,与全方组比较,DNA损伤作用明显增强,但微核形成率、精子畸形率未见明显改变。表明牛黄解毒片配伍可能会减低雄黄的遗传损伤作用,但具体药味尚不能明确与甘草、黄芩、大黄有关。
2.2.3牛黄解毒片配伍对雄黄肝肾毒性的影响采用病理组织学观察,分析牛黄解毒片配伍对雄黄肝肾毒性的影响。结果显示,雄黄组肝组织细胞显著水肿,局部有坏死；而肾脏组织出现局部肾小管细胞重度水肿；牛黄解毒片全方组及牛黄解毒片去雄黄组的肝肾组织未见明显异常,表明牛黄解毒片配伍能减低雄黄组肝肾毒性。
2.2.4牛黄解毒片配伍对肝肾组织氧化损伤的影响采用生物化学方法,测定各组肝肾组织脂质过氧化物MDA含量、抗氧化酶SOD和GSH-px的活力。结果显示,与阴性对照组及与牛黄解毒片全方组比较,雄黄组的肝、肾组织中GSH-px酶、SOD活力活力均显著下降(P<0.05),而MDA均明显升高(P<0.05),这表明雄黄的肝肾毒性可能与氧化损伤作用有关,而牛黄解毒片配伍减低雄黄肝肾毒性可能与抗氧化损伤有关。全方去甘草、黄芩、大黄组与全方组比较未见有明显差异,提示甘草、黄芩、大黄三味药在方中抗氧化尚不能明确。
2.2.5牛黄解毒片配伍对细胞凋亡的影响采用TUNNEL、免疫组化法测定牛黄解毒片配伍对肝细胞凋亡和凋亡相关分子表达的影响。结果显示,与阴性对照组比较,雄黄组的TUNEL阳性细胞数明显增加,Bax表达平均光密度明显增加,Bcl2表达平均光密度明显减少(P<0.05)：牛黄解毒片配伍后,TUNEL阳性细胞数较雄黄组明显减少,Bax表达平均光密度明显减少,Bcl2表达平均光密度明显增多(P<0.05)。这表明诱导肝细胞凋亡可能是雄黄引起肝损伤的可能机制；牛黄解毒片配伍对雄黄的诱导凋亡作用产生了抑制,抑制过程可能是通过促进Bcl2表达而阻碍bax表达来实现的。全方去甘草、黄芩、大黄组凋亡细胞数较全方组增加,Bax表达明显增加,但Bcl2表达无明显变化。
初步结论：牛黄解毒片配伍可以减低雄黄的砷毒性(肝肾毒性、遗传毒性),甘草、黄芩及大黄在方中可能是发挥减毒作用的重要药味,机制可能与减少可溶性砷的吸收与分布、抗氧化、抗凋亡有关。
The Niuhuang jiedu tablet is a representative of Qingrejiedu prescription in TCM, usually using for filled hot, sore throat, sore gums, tongue festered, red and swelling eyes and etc. For the evaluation Niuhuangjiedu security, the Ames test, chromosome aberration analysis, single cell gel electrophoresis assay (SCGE) and micronucleus tests were used, respectively, to explore the potential genotoxic effects of Niuhuang jiedu tablet. In addition, compatibility detoxification is one of the most characteristic methods and techniques for TCM, to explore whether the compatibility for Niuhuang jiedu tablet could reduce the toxicity of realgar and what is its possible mechanisms, different groups about Niuhuangjiedu tablet and its disassembled presciption were arranged, and soluble arsenic, arsenic in the body tissue distribution, pathological damage, oxidative damage, genetic damage, apoptosis etal, were detected.
1Genetoxicity evaluation for Niuhuang jiedu tablet
1.1Genetoxicity studies of Niuhuang jiedu tablet in in vitro bioassays
1.1.1Effects of Niuhuangjiedu tablet on gene reverse mutation Plate incorporation assay was adopted, in accordance with Maron, DM and Ames BN recommended procedures. Based on the pre-test results,5mg/dish was arranged as the highest dose group, then,1.5,0.5,0.15,0.05mg/dish, negtive and positive control groups were also arranged to carry out the experiment. The results showed no difference on gene reverse mutation of Trphoid Salmonella Strains, from0.05mg/dish to5mg/dish, both with and without S9mixture, and replies colonies number of various strains did not exceed2times the negative control group, and dose-response relationship was not showed.
1.1.2Chromosomal aberrations effect of Niuhuangjiedu tablet on CHL cells The IC50of Niuhuangjiedu tablet was determined as54μg.ml-1, by cell counting method. Dose range for chromosome aberration test was1.0,1/2,and1/4IC50values, i.e,54,27.13.5μg.ml-1respectively. The results showed that chromosome aberration rate of all dose group were less than5%, at24hrs exposure, and at9hrs exposure with the activation system S9, which is a negative response, chromosome aberration rate of the middle dose group was8.5%, which is greater than5%, and is a suspicious positive, at48hrs exposure, but chromosome aberration rate of high and low dose group is less than5%.
1.1.3DNA damage effect of Niuhuangjiedu tablet on CHL cells The DNA strand break effect of Niuhuangjiedu tablet on CHL cells was tested by SCGE. Dose range was also1.0,1/2,and1/4IC50values, i.e,54,27.13.5μg.ml-1respectively. The results showed DNA damage rised at the54μg.ml-1dose group after48hrs exposure in comparation with the negative control group, and the difference was significant (P<0.05), but there were no difference was found at medium and low dose group, which means Niuhuangjiedu tablet could induce DNA strand break of CHL cells at high dose.
1.2Genetoxicity studies of the Niuhuangjiedu tablet in in vivo assays
1.2.1The influence of Niuhuangjiedu tablet on chromosome integrity and separation changes Bone marrow PCE cell micronucleus test in mice exposed Niuhuangjiedu tablet through oral delivery with three dose groups (3345,1670,835mg.kg-1) was carried out, and two administering drugs regimens ("0" and "24" hrs administration at twice and6weeks continuous administration) were arranged. The results showed that the "0" and "24" hrs administration at twice, no significant difference (P>0.05)was found at each dose group,which suggested that under this regimen, the Niuhuangjiedu tablet had no influence on mice chromosome integrity and chromosome segregation. But under6weeks administration regimen, micronucleus rate at dose of1672mg.kg-1and3345mg.kg-1was found higher than that of negative control group (P <0.05), and the obvious dose-response relationship (r=0.999, P=0.023)was found, which means Niuhuangjiedu tablet could increase the mouse bone marrow cells micronucleus rate under long time administration.
1.2.2Sperm abnormality test in mice exposed to Niuhuangjiedu tablet Sperm abnormality test in mice exposed to Niuhuangjiedu tablet was carried out with three dose groups (3345,1670,835mg.kg-1), and the two administering drugs regimens (5d days administration and6weeks administration) were arranged. The results showed each dose group and the negative control group showed no significant difference (P>0.05) under two regimens, which means Niuhuangjiedu tablet has no significant genetic damage effect on germ cells in mice under this experimental conditions.
1.2.3DNA strand break of main tissues and organs cells in mice exposed to Niuhuangjiedu tablet SCGE technique was used to detect DNA strand breaks of peripheral blood cell in mice exposed to Niuhuangjiedu tablet, at different dose (3345,1670,835mg.kg-1) for different administration times (1w,2w,3w,4w and5w), and after the last administration, DNA strand breaks of mice lung, liver, kidney, spleen cell were also detected. The results showed that the DNA of peripheral blood lymphocytes began to perform strand breaks at administration2w or3w with high dose, and then significant DNA strand breaks were detected at all dose groups after administration4w or5w. Significant DNA strand breaks were also detected in cells of liver, lung cells at high and medium dose groups, and in renal cell at high dose groups, when compared with negtive control group, which indicates that Niuhuangjiedu tablet may induce DNA damage of liver, lung and renal cell after administration6w and through oral delivery.
Preliminary Conclusion:Niuhuangjiedu tablet had no obvious genetoxicity in in vitro and vivo experimental conditions, but with the increase of administration dose and the extension of administration time, which may have cumulative genetoxicity.
2The preniminary exploration on Niuhuangjiedu compatibility reducing realgar arsenic toxicity
2.1Determination of Soluble Arsenic in NiuhuangJiedu Tablet and its disassembled presciption Different groups about NiuhuangJiedu Tablet and its disassembled presciption were arranged, treated with artificial gastric juice or artificial intestine juice, then Atom Fluorescence Spectrophotometry(AFS) was used to detected the content of soluble Arsenic in the different groups samples. The result showed the content of soluble Arsenic in the whole presciption of NiuhuangJiedu Tablet was significant lower than that in the single relgar (P<0.01), the content of soluble Arsenic in the whole presciption with Gancao,Hangqin,Dahuang excluded was significant higher than that in the whole presciption of NiuhuangJiedu Tablet (P<0.01),which suggested the compatibility for Niuhuangjiedu Tablet could reduce the toxicity of realgar,and Gancao,Hangqin and Dahuang may be the possible herbal medicines that play the role of reducing toxicity.
2.2Animal experiment studies on Niuhuangjiedu Tablet compatibility reducing realgar arsenic toxicity
2.2.1The influence of Niuhuangjiedu tablet compatibility on the absorption and distribution of arsenic in realgar The AFS was used to detect and analye the influence of Niuhuangjiedu tablet on the absorption and distribution of arsenic in realgar. The results showed arsenic content in liver, kidney, spleen, heart and lung tissue in the single realgar was significantly higher than that of negtive group after administration9W (P<0.05), which confirmed that the arsenic in realgar could be absorpted and distributed in bodies. Compared with the whole presciption of NiuhuangJiedu Tablet, arsenic content in liver, kidney, spleen, heart and lung tissue in realgar was significantly higher (P<0.05), and arsenic content in liver, spleen, heart tissue in the whole presciption with Gancao,Hangqin,Dahuang excluded was also significant higher (P<0.05) which suggested the compatibility for Niuhuangjiedu Tablet could reduce the absorption and distribution of arsenic in realgar, and the absorption and distribution of arsenic in realgar may increase if Gancao, Hangqin.Dahuang in whole presciption of NiuhuangJiedu Tablet are excluded.
2.2.2The influence of Niuhuangjiedu tablet compatibility on the oxidative stress The lipid peroxide product MDA and antioxidant enzymes SOD and GSH-px were determined to explore the influence of Niuhuangjiedu tablet compatibility on the oxidative damage. The results showed GSH-px enzyme activity in the liver, kidney, lung, heart tissue and SOD enzyme activity in liver kidney, spleen tissue decreased significantly (P<0.05).and MDA content in liver, kidney, heart tissue increased significantly (P<0.05),when single realgar compared with the negtive group. However, the GSH-px and SOD enzyme activity and MDA content in the whole presciption and in the whole presciption with Gancao, Hangqin, Dahuang excluded showed no significant change (P>0.05), which indicates that the realgar could cause oxidative damage, and Niuhuangjiedu compatibility could reduce oxidative damage caused by realgar, but which are the main herbs that play the role of antioxidative damage may not be determined.
2.2.3The influence of Niuhuangjiedu tablet compatibility on genetic damage Comet technology, the micronucleus test, etc were used to determined the influence of Niuhuangjiedu tablet compatibility on genetic damage. The results showed the DNA damage in peripheral blood cell, micronucle formation rate in bone marrow PCE cell, and the sperm abnormality rate in single realgar increased signiffcantly (P<0.05),when compared with the negative group. DNA damage, micronucleus formation rate decreased signiffcantly (P<0.05), sperm abnormality rate had no signiffcant difference in the whole presciptio of Niuhuangjiedu tablet in comparation with single realgar; DNA damage, micronucle formation rate and sperm abnormality rate in the whole presciption with Gancao,Hangqin,Dahuang excluded showed no significant change. These results indicates that the Niuhuangjiedu compatibility could reduce the genetic injury of realgar, but the specific herbs that play role of antigenetic damage was not yet determined.
2.2.4The influence of Niuhuangjiedu tablet compatibility on liver and kidney toxicity The pathological and hisological observation was used to analye the influence of Niuhuangjiedu tablet compatibility on liver and kidney toxicity of realgar. The results showed that liver tissue in the realgar was significantly edema, local necrosis; and local renal tubular cells in kidney tissues in the realgar was severe edema; The liver and kidney tissues showed no abnormal changes except local edema in the whole presciption of NiuhuangJiedu Tablet and the whole presciption with realgar excluded, which suggested Niuhuangjiedu tablet compatibility may could reduce the liver and kidney toxicity of realgar. The liver tissue showed mild edema and kidney tubular epithelial cells showed moderate edema in the whole presciption with Gancao, Hangqin, Dahuang excluded, which indicates the liver and kidney toxicity may be enhanced with Gancao, Hangqin, Dahuang removed from the whole presciption of NiuhuangJiedu.
2.2.5The influence of Niuhuangjiedu tablet compatibility on liver apoptosis The TUNEL and immunohistochemical methods were used to determine the influence of Niuhuangjiedu tablet compatibility on liver apoptosis and apoptosis related molecules expression. Results showed the TUNEL positive cell numbers and mean density of Bax expression increased significantly, but mean density of Bcl2expression reduced significantly, when realgar group compared with negative group (P<0.05). However, TUNEL-positive cell numbers and mean density of Bax expression decreased significantly, and mean density of Bcl2expression increased significantly, when the whole presciption compared with the single realgar (P<0.05), indicates the Niuhuangjiedu compatibility may inhibit liver apoptosis that realgar induced, and such inhibition may be achieved by promoting bcl2expression and inhibiting bax expression. The whole presciption with Gancao, Hangqin, Dahuang excluded in compared with the whole presciption, the TUNEL positive cell numbers and mean density of Bax expression increased significantly, but mean density of Bcl2expression had no apparent changes, which indicated Gancao, Hangqin. Dahuang in the whole presciption may reduce the liver toxicity of realgar by antiapoptosis.
Preliminary Conclusion:The compatibility of Niuhuangjiedu tablet may reduce the asenic toxicity of realgar, and reducing absorption and distribution of soluble arsenic, antioxidative damage, antiapoptosis, and et al maybe the possible mechanisms. The specific herbs that reduced asenic toxicity of realgar were not yet determined in this study, which needs further research.
引文
[1]中国药典[S]·一部·2010：386.
[2]张力,高思华,周超凡,等.从牛黄解毒丸(片)看含砷中成药的安全性问题[J].中国中药杂志,2006,31(23).
[3]庄洁,景丽华.牛黄解毒丸(片)引起不良反应38例分析[J].中国药房,1998,9(6)：274-275.
[4]蓝美成.牛黄解毒片(丸)不良反应58例临床分析[J].医学文选,2000,19(6)：911-913.
[5]金笑颜.牛黄解毒片(丸)引起不良反应16例分析[J].青海医学杂志,1999,29(8)：60-61.
[6]吴丽兰,应小飞,金华英,等.67例牛黄解毒丸(片)不良反应分析[J].中成药2002,24(7)：562-564.
[7]邹明畅,倪鸿昌牛黄解毒片(丸)40例不良反应分析.世界临床药物[J],2007,28(1)：44-46.
[8]铁步荣,乔旺忠,马忠明,等.人服用含雄黄中成药后尿中砷含量的动态研究[J].中国中药杂志,1992,17(5)：285-288.
[9]万丽,黄珍,赵力.等.牛黄解毒片中砷的体内吸收与分布——牛黄解毒片中雄黄的系统研究(Ⅱ)[J].时珍国医国药,2004,14(5)：257-258.
[10]张力,高思华,周超凡,等.从牛黄解毒丸(片)看含砷中成药的安全性问题[J].中国中药杂志,2006,31(23)
[11]姜泓,费思平,陈再兴,等.氢化物冷阱捕集原子荧光光度法测定人工胃液、水中牛黄解毒片可溶性砷的含量[J].中药材.2008.31(3)：450-452.
[12]傅丽玲,周宗灿.宫恩聪,等.牛黄解毒片经口对大鼠的急性和14天毒性[J].北京医科大学学报,1997,29(6)：546.
[13]张桥主编.卫生毒理学基础[M].北京：人民卫生山版社,2000,138.
[14]张天宝.当前遗传毒理学的研究动态[J].毒理学杂志,2007,21(5)：359-365.
[15]张春颖,周钟鸣.常见中药的致突变性研究进展[J].中国中医药信息杂志,2001,8(3)：20
[16]王钦茂.李莉,方华武,等.中药致癌、致突变和生殖毒性研究概况[J].安徽中医学院学报,2001,20(5)：64-67.
[17]王瑞,胡边,殷学军.中药遗传毒理学研究进展[J].中成药,2002,24(1)：57-59.
[18]孙耀光,李保兰.中医药抗诱变和抗突变作用[J].陕西中医学院学报,2005,28(5)：59-61.
[19]马哲,梁茂新.中药配伍减毒增效研究现状、问题与思考[J].辽宁中医药大学学报,2011,13(8)：187-190.
[20]李军生,路燕,邹义英.中药配伍减毒及其应用[J].中医杂志,51(增刊1)：43-45.
[21]郭盛.唐于平.宿树兰.近10年来中药配伍减毒的现代研究进展[J].中国实验方剂学杂志.2008,,14(10)：74-79.
[22]孟锐,孙建飞,唐冬蕾,等.中成药安全性评价研究现状及其基本对策的探讨[J].中医药信息,2005,22(6)
[23]New zealand medicines and medical devices safety authorityMediareleases 2003:Director-generals' privileged statement under section98 of themedicines act 1981-traditional Chinese medicine[N]·http:www medsafe·govtnz/hot/media/media2003·htm, 2003-01-21·
[24]Medicines and healthcare products regulation agency·Herbal safe-ty news:Niu Huang Jie Du Pian[N]·http: //www·mhra·gov·uk/home/idcplg?IdcService=SS GET PAGE&nodeId=664, 2003-01-17·
[25]Environment Health Criteria 18[S]:Arsenic WHO. Geneva,1981.
[26]白爱梅,李跃,范中学.砷对人体健康的危害[J].微量元素与健康,2007(01)
[27]地方性砷中毒防治手册.哈尔滨：中国疾病预防控制中心地方病控制中心,2005.7.
[28]田小藕.谈雄黄及其用量[J].中国中医药信息杂志,2006,13(9)
[29]孙恩亭,卜新柱.中药雄黄的致突变性实验研究[J].中国中医基础医学杂志,1998,4(11)：52.
[30]张天宝.新药遗传毒性评价方法的研究现状和发展趋势[J].癌变.畸变.突变,2002,14(4)：243-246.
[31]中华人民共和国国家标准,食品安全性毒理学评价程序和方法[S](GB15193-2003)
[32]Maron DM and Ames BN.Revised methods for the Salmonella mutagenicity test[J].Mutation Research 1983,113(2):173-215.
[33]中华人民共和国药政局,汇编.新药临床前研究指导原则(药学药理学毒理学)[M].1993,211-213
[34]刘国廉主编,细胞毒理学[M].第一版,北京：军事医学科学出版社出版,2001,196-211.
[35]Singh NP,McCoy MT,Tice RR,et al.A simple of technique for quantitation of low levels of DNA damage in individual cells[J].Exp Cell Res,1988,175:184-191.
[36]Mckelvey-Martin VJ,Green MH,Schmezer P, et al. The single cell gel electrophoresis assay (comet assay):a European review[J].Mutat Res,1993,288:47-63.
[37]朱文文,王晓涛,DNA损伤检测--单细胞凝胶电泳技术的研究[J].微量元素与健康研究,2007,24(3)：6-7.
[38]胡启之OECD新发布急性经口毒性试验方法简介[J].毒理学杂志,2005,
[39][ZH]GPT2-1,药物遗传毒性研究技术指导原则[S],国家食品药品监督管理局,国食药监注[2007]643号.
[40]Sasaki YF, Lzumiyama F,Nishidate E,et al.Detection of roden liver carcinogen genotoxicity by the alkaline single cell gel electrophoresis assay in multiple mouse organs(liver lung spleen kidey and bone marrow)[J].Mutat Res,1997,391:201-214
[41]刘嵘,濮德敏.雄黄的研究进展[J].时珍国医国药,2007,18(4)：982-984.
[42]岳旺,刘文虎,王兰芬,等.中国矿物药的急性毒性测定[J].中国中药杂志,1989.14(2)：42.
[43]康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察[J].时珍国医国药,1998,9(4)：322.
[44]李信民,陈思宇,王怀宇,等.瑞尔康主成分雄黄的动物急性毒性试验[J].现代中医,2001,1：43-44.
[45]仝燕,张英军,李先荣.湖南石门雄黄的研究[J].中国中医药科技,1997,4(5)：286.
[46]张伟,余伯阳,寇俊萍,等.雄黄活性物质的毒效相关性初步研究[J].中国天然药物,2004,2(2)：123-125.
[47]张亚敏,纪淑芳,蔡连之,等.雄黄生品与酸奶飞炮制品的毒理学比较[J].长春中医学院学报,2000,16(1)：46.
[48]范麒如,寇俊萍,张伟,等.天然雄黄与精制雄黄对小鼠肝脏损伤的初步研究[J].中国天然药物[J]，2007,5(1)：63-66.
[49]孙恩亭,卜新柱,钱怡宁,等.中药雄黄的致突变性实验研究[J].中国中医基础医学杂志,1998,4(11)：52.
[50]董菊,詹臻,王明艳.彗星试验检测雄黄对中国仓鼠肺细胞DNA的损伤作用[J].上海中医药杂志,2009,43(3)：79-81.
[51]汤毅珊,欧卫平,王宁生.等.雄黄单次或多次给药在大鼠体内的药代动力学和组织分布[J].中药药理与 临床,2009,25(3)：39-42.
[52]张娟,汤毅珊,刘启德.雄黄中砷的毒代动力学及组织学分布[J].中国中药杂志,2010,35(13)1750-1753.
[53]红缨,滕智平,陆道培,等.四硫化四砷对急性早幼粒细胞白血病细胞株NB4的凋亡作用[J].中国药理学与毒理学杂志,2002,16(1)：37.
[54]梁国刚.张启伟.朱砂、雄黄中各成分的溶解度对其药效、毒副作用的影响[J].中国中药杂志,2002,27(5)：391-392.
[55]叶祖光,王智民,王跃生,等.安宫牛黄丸中朱砂和雄黄的药理作用特点与安全性评价研究[J].医学研究通讯,2005.34(9)：35
[56]潘英伟,陈卫平,奚丽君.甘草减毒作用的应用与机理分析[J].南京中医药大学学报,2008,24(6)：428-430.
[57]邰昌松,王振宇,贾光,等.牛黄及制剂对正己烷致小鼠肝、肾脂质过氧化的保护作用研究[J],中国职业医学,2006,33(6)：417-419.
[58]傅乃武,刘朝阳,张如意.甘草黄酮体抗促癌、抗致突和抗氧化作用的研究[J].天然产物研究与开发,1995,7(4)：29-34.
[59]KITCHIN K T, AHMAD S. Oxidative stress as a possible mode of action for arsenic carcinogenesis[J]. Toxicol Lett,2003,137(122):3213.
[60]Li Z, An Y. Advance on oxidative stress mechanism of arsenic[J].Wei Sheng Yan Jiu, 2009,38(5):634-636.
[61]Hartmann A, Speit G. Comparative investigations of the genotoxic effects of metals in the single cells gel (SCG) assay and the sister chromatid exchange(SCE) test[J]. Environ Mol Mutagen,1994, 23 (4):299-305.
[62]Kligerma AD,Tennant AH.Insights into the carcinogenic mode of action of arsenic[J]. Toxicol Appl Pharmacol, 2007, 222(3):281-288.
[63]张志杰,周群,尉京志,等.我国药用雄黄的晶体结构鉴定[J].光谱学与光谱分析,2011,31(2)：291-296.
[64]国家药典委员会.中华人民共和国药典[S].二部.北京：化学工业出版社,2005：附录76.
[65]中华人民共和国国家标准,食品卫生检验方法理化部分(一).北京：中国标准出版社,2004.
[66]宋成岩.刘宇,朴锦花,等.黄芩抗氧化化学成分的研究[J].时珍国医国药,2007,18(4)：856-857.
[67]陶玉珍,刘毅,郭启明,等.大黄抗突变作用的研究[J].癌变·畸变·突变,1998,10(4)：41-243.
[68]姜泓,孟舒,陈再兴,等.氢化物发生冷阱捕集原子荧光光度法测定人工肠液、水中牛黄解毒片中可溶性砷的含量[J].中药材,2009.32(4)：629-631.
[69]刘海涛.AFS法在重金属元素分析中的应用及创新[J].食品安全导论,2010,(01)。
[70]白爱梅,李跃,范中学.砷对人体健康的危害.微量元素与健康研究[J].2007,24(1)：61-62。
[71]张景红,樊秦,李红玉.雄黄及微生物炮制液砷形态和毒性分析[J].中药材,2010,33(5)：684-688。
[72]盖秀兰.有毒微量元素砷的毒性研究[J].白城师范学院学报,2006,20(4)：36-38.
[73]李贞,安艳.砷毒性作用氧化应激机制研究进展[J].卫生研究,2009,38(5)：634-640.
[74]唐功.活性氧·抗氧化酶及抗氧化剂之间关系的探讨[J].安徽农业科技,2010,38(33)：18619-18621.
[75]孙鲜策,蔡竹,刘爽,等.GSH对砷氧化损伤保护作用的研究[J].大连医科大学学报,2008,30(6)：500-502
[76]徐敏.论人体的自由基和抗氧化剂-谷胱甘肽[J].中国医药导报,2006,3(2)：127.
[77]杨琳,廖明芳,季欣然,等.超氧化物岐化酶在医学领域的研究现状[J].现代生物医学进展,2010,10(2)：396-310.
[78]杨湘山,李景舜,吕焱,等.生姜提取物对X射线损伤小鼠肝脏脂质过氧化的影响[J].现代预防医学,2007,34(3)：436-437.
[79]洪莉,蔡威.凋亡与肝细胞损伤机制的研究进展[J].临床小儿外科杂志,2006,5(1)：42.
[80]刘文兰,张颖.细胞凋亡检测方法——TUNEL[J]解剖科学进展,1999,5(4)：330-332.
[81]陈春莲,蓝儒竹,叶章群,等TUNEL技术方法的探讨[J].同济医科大学学报,2001,30(3)：274-276
[82]]李晶媛,李树臣,杨维良TNF-a诱导肝细胞凋亡机制的回顾与展望[J].世界华人消化杂志,2007,15(6)：606.
[83]Ogretmen B,Safa A R.Down-regulation of apoptosis-related bcl-2 but notbcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breastcancer cells[J].Int J Cancer, 1996,67 (5):608.
[84]Brooks C, Dong Z.Regulation ofmitochondrialmorphological dy-namics during apoptosis by Bcl-2 family proteins:a key in Bak?[J].CellCycle,2007,6(24):3043-3047.
[1]张志杰,周群,尉京志,等.我国药用雄黄的晶体结构鉴定[J].光谱学与光谱分析,2011,31(2)：291-296.
[2]江苏新医学院主编.中药大词典[M].上海：上海人民出版社,1977：23-27.
[3]Medicines and healthcare products regulation agency-Herbal safe-ty news:Niu Huang Jie Du Pian.http:// www·mhra·gov·uk/home/idcplg IdcService= SS GET PAGE&nodeld= 664,2003-01-17.
[4]岳旺,刘文虎,王兰芬,等.中国矿物药的急性毒性测定[J].中国中药杂志,1989,14(2)：42.
[5]康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察[J].时珍国医国药,1998,9(4)：322.
[6]仝燕,张英军,李先荣.湖南石门雄黄的研究[J].中国中医药科技,1997,4(5)：286.
[7]李信民,陈思宇,王怀宇,等.瑞尔康主成分雄黄的动物急性毒性试验[J].现代中医,2001,1：43-44.
[8]张伟,余伯阳,寇俊萍,等.雄黄活性物质的毒效相关性初步研究[J].中国天然药物,2004,2(2)：123-125.
[9]张亚敏,纪淑芳,蔡连之,等.雄黄生品与酸奶飞炮制品的毒理学比较[J].长春中医学院学报,2000,16(1)：46.
[10]范麒如,寇俊萍,张伟,等.天然雄黄与精制雄黄对小鼠肝脏损伤的初步研究[J].中国天然药物[J],2007,5(])：63-66.
[11]孙恩亭,卜新柱,钱怡宁.等.中药雄黄的致突变性实验研究[J].中国中医基础医学杂志,1998,4(11)：52.
[12]董菊,詹臻,王明艳.彗星试验检测雄黄对中国仓鼠肺细胞DNA的损伤作用[J].上海中医药杂志,2009,43(3)：79-81.
[13]吴文斌,汤家铭,祝晓雯,等.中药雄黄对孕大鼠母体和胚胎-胎仔发育的毒性[J].毒理学杂志,2009,23(5)：380-383.
[14]叶祖光,王智民,王跃生.等.安宫牛黄丸中朱砂和雄黄的药理作用特点与安全性评价研究[J].医学研究通讯,2005,34(9)：35.
[15]汤毅珊,欧卫平,王宁生,等.雄黄单次或多次给药在大鼠体内的药代动力学和组织分布[J].中药药理与临床,2009,25(3)：39-42.
[16]张娟,汤毅珊,刘启德.雄黄中砷的毒代动力学及组织学分布[J].中国中药杂志.2010,35(13)：1750-1753.
[17]张力,高思华,周超凡,等.从牛黄解毒丸(片)看含砷中成药的安全性问题[J].中国中药杂志.2006,31(23)
[18]傅丽玲,周宗灿,宫恩聪,等.牛黄解毒片经口对大鼠的急性和14天毒性[.J].北京医科大学学报,1997,,29(6)：546.
[19]董菊,唐萌,王姝.牛黄解毒片的遗传毒性研究[J].癌变.畸变.突变,2009.21(6)：477-478.
[20]万丽,黄珍,赵力.牛黄解毒片中砷的体内吸收与分布—牛黄解毒片中雄黄的系统研究[J].时珍国医国药,2003,14(5)：257-258.
[21]林飞,宋谊萍.中药清心丸的遗传毒性研究[J].癌变.畸变.突变,1995,7(5)：280.
[22]林飞,宋谊萍.中药清心丸的致畸毒性研究[J].癌变.畸变.突变,1995,7(4)：243.
[23]Liu J, Liang SX,Lu YF. Realgar and realgar-containing Liu-Shen-Wan are less acutely toxic than arsenite and arsenate. J Ethnopharmacol,2011 Mar 8; 134(1):26-31. Epub 2010 Dec 1.
[24]齐卫红,李欣,沈连忠,等.Beagle犬经口给予六神丸急性毒性研究[J].毒理学杂志,2007,21(4)：303.
[25]齐卫红,沈连忠,李欣,等Beagle犬重复给予六神丸28 d及恢复期14 d毒性研究[J].毒理学杂志2007,21(4)：304.
[26]Lu YF, Yan JW, Wu Q, et al. Realgar and cinnabar con taining An Gong Niu Huang Wan(AGNH) is much 1 ess acutely tox ic th an sodium arsenite and mercuric chloride [J]. Chem Biol Interact, 2011, 189(12):134-140.
[27]Lu YF, Wu Q, Yan JW, et al. Realgar, cinnabar and An Gong Niu Huang Wan are much less chronically nephrotoxic than common arsenicals and mercurial [J]. Exp Biol Med(May wood),2011,236(2):233-239.
[1]Ostling O, Johanson K J.Microelectrophoretic study of radiation2induced DNA damages in individual mam Malian cells[J].Bioehem Biophys Res Commun,1984, (123):37-40.
[2]Singh N P,Stephens R E.Micro gel electrophoresis:Sensitivity, mechanisms, and DNA electrostretching [J].MutRes,1997,(383):167-175.
[3]田云,卢向阳,易克,等.单细胞凝胶电泳技术[J].生命的化学,2004,24(1)：77-78.
[4]朱文文,王晓涛.DNA损伤检测--单细胞凝胶电泳技术的研究[J].微量元素与健康研究,2007,24(3)：6-7.
[5]李彦,谢明.单细胞凝胶电泳技术操作方法介绍[J].生物学通报,2005,40(7)：50--53.
[6]江励华.中药抗DNA损伤作用的研究[J].医药导报,2004,23(4)：250-252.
[7]杨敏.仙草提取物对小鼠脾淋巴细胞DNA氧化损伤保护作用的研究[J].浙江大学学报(医学版),2006,35(1)：35-38.
[8]路萍,赖炳森,李植峰,等.白黎芦醇体外抗氧化活性和对细胞DNA损伤防护作用的实验研究[J].中医药学报,2004,32(1)：50-52.
[9]路萍,赖炳森,梁萍,等.姜油体外抗氧化活性和对细胞DNA损伤防护作用的实验研究[J].中国中药杂志,2003,28(9)：873-875.
[10]王晖,张杰,张淑华,等.甜杏仁对H2O2诱导大鼠外周淋巴细胞DNA损伤的影响[J].首都医科大学学报,2007,28(5)：609-612.
[11]王洪侠.桑叶及桑白皮对老龄小鼠脾细胞DNA氧化损伤影响[J].赤峰学院学报,2007,23(3)：77-79.
[12]马庆华,张鹏霞,郭红艳,等.白术多糖对D_半乳糖致衰大鼠神经细胞抗氧化作用研究[J].中国老年学杂志,2006,12(26)：1658--1659.
[13]张慧丹,孙洁,欧芹,等.衰老HDF细胞DNA损伤与HSP70 mRNA表达及山茱萸多糖的作用[J].中国老年学杂志,2009,29(16)：2007-2009.
[14]陈刚,毛珺.脾肾双补法对衰老小鼠胸腺细胞DNA氧化损伤修复的影响[J].中国现代医生,2007,45(13)：90-91.
[15]王瑞,胡边,殷学军.中药遗传毒理学研究进展[J].中成药,2002,24(1)：57-59.
[16]王小红,夏明珠,龙文,等.黄芩的致突变性研究[J].新中医,2000,2(10)：30-31.
[17]王小红,江洪,夏明珠,等.姜半夏致突变性实验研究[J].江苏中医药,2002,23(8)：42-43.
[18]周东升,袁慧.杜仲提取物对小鼠淋巴细胞DNA损伤的研究[J].中曾医学杂志,2005,5：11-13.
[19]王金勇,王亚其,张建军,等.鸟头类中药对CHL细胞的DNA损伤作用[J].现代预防医学,2007,34(7)：1204-1206.
[20]肖立峰,张天虹,刘江涛,等.中药薏苡仁酯作用喉癌Hep_2细胞的体外研究[J].哈尔滨医科大学学报,2004,38(3)：252-253.
[21]魏雪涛,蒋建军,吴涛,等.姜黄素拮抗亚砷酸钠所致的DNA链断裂损伤[J].药学学报,2002,37(11)：833-836.
[22]周敏,周慧.姜黄素对长波紫外线所致DNA损伤的拈抗作用[J].山西医药杂志,2004.33(12)：1031-1033.
[23]曹军,姜丽华,耿成燕,等.姜黄素对丙烯酰胺致HepG2细胞DNA损伤的保护作用[J].卫生研究,2009,38(16)：392-394.
[24]黄炜,陈新美,张志凌,等.18_甘草次酸诱导人乳腺癌细胞凋亡及其细胞内Ca2+水平的变化[J].中国癌症杂志.2006,16(2)：102-106.
[25]陈新美,黄炜,张志凌,等.甘草酸诱导人乳腺癌细胞凋亡和细胞内Ca2+的相关性研究[J].中国现代医学杂志,2006,16(24)：3729-3732.
[26]王春玲,傅攀峰,李宏伟,等.葛根素对血管内皮细胞DNA损伤的保护作用[J].中国微循环,2004,8(6)：361-364.
[27]刘鹏,曹魏,岳志军,等.中药复方“益糖康”抗糖尿病大鼠DNA损伤的实验研究[J].中国中医基础医学杂志,2002,8(10)：15-16.
[28]李瑛,刘志红,郭啸华,等.马兜铃酸Ⅰ致肾小管上皮细胞DNA损伤的实验研究[J].肾脏病与透析肾移植杂志,2004,13(1)：7-11.
[29]王大方,高广,杨静玉,等.正交设计法研究麻黄汤对小鼠外周血淋巴细胞DNA的损伤作用[J].中药药理与临床,2006,22(3,4)：7-9.
[1]王冬娜.中药对恶性肿瘤化疗减毒作用的研究进展[J].时珍国医国药,2008,19(1)：242-243.
[2]阴健,郭力弓.中药现代研究与临床应用[M].北京：学苑出版社,1993：5922605.[3]中华人民共和国卫生部医政司编.中国常见恶性肿瘤诊治规范(第九分册)[M].北京,北京医科大学,
中国协和医科大学联合出版社,1992：9-15.
[4]孙燕,周际昌.临床肿瘤内科手册[M].第四版,北京,人民卫生出版社,2003：106-107.
[5]李廷谦,李幼平,王刚.中西医结合循证医学[M].第1版,上海,上海科学技术出版社,2006：318.
[6]段萍,王再漠,黄芪在恶性肿瘤的化疗中的增效减毒作用的临床研究[J].中国中西医结合杂志,2002,22(7)：515-517.
[7]甘宁,陈焕朝.黄芪注射液辅助化疗治疗老年肺癌的疗效观察[J].肿瘤防治研究,2004,3(7)：433-434.
[8]唐黎,武明花.黄芪注射液联合化疗治疗恶性肿瘤临床观察[J].中国医师杂志,2006,8(3)：425-426.
[9]万丽娜,冯刚.黄芪注射液联合化疗治疗恶性肿瘤的临床研究[J].中国药房,2009,20(9)：703-705.
[10]王和融,檀朝甲.黄芪注射液对肿瘤患者化疗的减毒作用[J].中国中医药科技,2005,12(6)：407-408.
[11]张春霞.黄芪注射液对中晚期非小细胞肺癌化疗后骨髓系统的影响[J].海南医学学报,2007,13(5)：437-438.
[12]邹雨荷,刘雪梅.黄芪注射液配合化疗对晚期非小细胞肺癌患者生存质量的影响[J].中国中西医结合杂志.2003.10.23(10)：733-735
[13]杜现华,桂心佳,张克信等.黄芪注射液配合化疗治疗恶性肿瘤临床观察[J].上海医药,2000,21(2)：16-18.
[14]王红,王莉,雷秋模.大剂量黄芪注射液联合化疗治疗恶性肿瘤临床观察[J].江西中医药,2006,12,37(288)：43-44.
[15]潘峰.黄芪注射液辅助化疗增效减毒临床研究[J].山东中医药大学学报,2003,3,27(2)：137-139.
[16]蔡丰穗,王在国.黄芪注射液联合化疗在治疗恶性肿瘤中的应用[J].中医中药,2009,7,6(19)：130-131.
[17]李艳丽.黄芪注射液联合化疗治疗恶性肿瘤临床观察[J].中华实用中西医杂志,2002,2(15)：1348-1349.
[18]许红娟,陈敏珠.黄芪多糖的抑瘤作用及其机制[J].中国医院药学杂志,2005,25(10)：923-925.
[19]刘莎,符州.黄芪的免疫调节作用及临床应用[.J].国际中医中药杂志.2006,28(4)：203-205.
[20]解庆东,赵慧男.黄芪抗肿瘤机制研究与临床应用[J].医药导报,2003,22(2)：109-110.
[21]Suresh R, Chandra P. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions[J].The Oncologist.2008,3(suppl 1):5-12
[22]D'Addario G, Pintilie M, Leighl NB,et al.Platinum-based versus nonplatinum-based chemotherapy in advanced non-small-cell lung cancer:a meta-analysis of the published literature[J].J Clin Oncol,2005,23(13): 2926-2936
[23]陆益,陆益线.参芪扶正注射液的药理作用和临床应用[.J].时珍国医国药,2006,17(10)：2083-2085.
[24]Higgins J. Green S (eds). Cochrane handbook for systematic reviews of interventions 4.2.6. In The Cochrane library,301 Issue 4. Wiley:Chichester (updated September 2006),2006.
[25]WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Orgnaization,1979
[26]全国肿瘤防治办公室等合编.中国常见恶性肿瘤诊治规范(原发性支气管肺癌).北京：北京医科大学、中国协和医科大学联合出版社,1990：1-19.
[27]Yates JW, Chalmer B, McKegney FP:Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer, 1980,45:2220-2224
[28]Guyatt GH, Sackett DL, Cook DJ. Users' guides to the 309 medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working GroupJAMA,1993,270:2598-2601
[29]郝秀丽,吕晓君.参芪扶正注射液对晚期非小细胞肺癌化疗患者生存质量的影响[J].实用肿瘤学杂志,2008,22(5)：458-459
[30]王昆,覃建雄,农云.参芪扶正注射液联合NP化疗方案治疗晚期非小细胞肺癌临床观察[J].现代中西医结合杂志,2007,16(26)：3797-3798
[31]康桂艳,李波.参茂扶正注射液联合化疗治疗晚期非小细胞肺癌36例[J].中国中西医结合杂志,2006,26(6)：565-566
[12]龚志敏,王言,余川运,等.参芪扶正注射液配合NP方案化疗治疗老年晚期非小细胞肺癌疗效观察[J].中国中医药信息杂志,2008,15(9)：64-65
[33]汪秀云,黄宗琼,李虹,等.参芪扶正注射液辅助NP方案治疗老年晚期非小细胞肺癌的观察及护理[J].中国肺癌杂志,2007,10(3)：234-236
[34]王玉洲,杨志雄,廖思海,等.参芪扶正注射液联合国产长春瑞滨+卡铂方案治疗晚期非小细胞肺癌临床观察[J].临床内科杂志,2007,24(3)：206-207
[35]李铁文,向丽,童方友,等。参芪扶正注射液联合化疗治疗晚期肺癌临床观察[J].现代生物医学进展,2009,9(10)：1917-1919
[3]李勇,陈思现,黄瑞文.参芪扶正注射液配合NP方案治疗晚期非小细胞肺癌的临床观察[J].中国现代医药杂志,2007,9(3)：40-41
[37]吕靖.参芪扶正注射液辅助化疗治疗晚期非小细胞肺癌临床观察[J].中国医药导,2008,5(36)：73-74
[38]赵作银,吴德林,陈猛,等.参芪扶正注射液辅助NP方案治疗老年晚期非小细胞肺癌近期疗效[J].现代肿瘤医学,2007,15(1)：42-43
[39]耿丽.参芪扶正注射液联合化疗治疗非小细胞肺癌[J].医药论坛杂志.2004.25(17)：29-30
[40]于清忠.参芪扶正注射液联合化疗治疗中晚期非小细胞肺癌[J].中国中西医结合杂志.2007.27(5)：473-474
[41]刘城林,陈为平,崔书中,等.参芪扶正注射液辅助化疗治疗老年非小细胞肺癌临床观察[J].中国中医结合杂志,2004,24(10)：901-903.
[42]刘鹏辉,廖国清,王红酶.参芪扶正注射液配合化疗治疗晚期肺癌的近期疗效[J].第三军医大学学报,2007,29(3)：259-260.
[43]潘彦康,黄敏,区梅.参芪扶正注射液辅助化疗治疗非小细胞肺癌临床观察[J].中国临床医生杂志,2008,3(4)：43-45.
[44]郑加辉,陈有法.参芪扶正注射液联合NP方案治疗晚期非小细胞肺癌42例[J].江西中医药,2009,40(6)：58-59.
[45]邹彦,柏玉举,阮培刚.参芪扶正注射液联合紫杉醇加卡铂治疗晚期非小细胞肺癌临床观察[J].实用肿瘤杂志,2005,20(3)：260-262.
[46]罗世政,龙金华,余祥艳.参芪扶正注射液联合紫杉醇加顺铂治疗晚期非小细胞肺癌的临床观察[J].肿瘤研究与临床,2006,18(3)：181-183.
[47]罗社文,黄燕苹,陕海丽,等.参芪扶正注射液联合紫杉醇加顺铂治疗中晚期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2007,12(5)：381-38.
[48]张福林.参芪扶正注射液配合紫杉醇加顺铂治疗中晚期非小细胞肺癌的临床观察[J].现代肿瘤医学,2008,16(7)：1165-1166.
[49]赵艳勋,王春雨,李静,等.参芪扶正注射液联合TP方案治疗非小细胞肺癌疗效观察[J].中国误诊学杂志.2009,19(21)：5129-5130.
[50]于飞,李凯.参芪扶正注射液辅助化疗治疗非小细胞肺癌临床观察[J].中国中西医结合杂志,2007,21(2)：166-167.
[51]何文杰,赵金奇.参芪扶正注射液联合吉西他滨加顺铂方案治疗晚期非小细胞肺癌的临床观察[J].中国肿瘤学进展,2008,6(4)：432-434.
[52]Michael Borens t ein, L. V. Hedges, J. P. T. Higgins, et al. Introduction to Meta-Analysis. Rothstein (?) John Wiley & Sons, Ltd.2009
[53]薄芯,董历平,屠蘅菁,等.黄精、党参和绿茶减轻环磷酰胺毒副作用初探[J].中医研究,1997,10：20-22.
[54]王润田,单保恩,李巧霞,等.黄芪提取物免疫调节活性的体外实验研究[J].中国中西医结合杂志,2002,2：453-455.
[2]张力,高思华,周超凡,等.从牛黄解毒丸(片)看含砷中成药的安全性问题[J].中国中药杂志,2006,31(23).
[3]庄洁,景丽华.牛黄解毒丸(片)引起不良反应38例分析[J].中国药房,1998,9(6)：274-275.
[4]蓝美成.牛黄解毒片(丸)不良反应58例临床分析[J].医学文选,2000,19(6)：911-913.
[5]金笑颜.牛黄解毒片(丸)引起不良反应16例分析[J].青海医学杂志,1999,29(8)：60-61.
[6]吴丽兰,应小飞,金华英,等.67例牛黄解毒丸(片)不良反应分析[J].中成药2002,24(7)：562-564.
[7]邹明畅,倪鸿昌牛黄解毒片(丸)40例不良反应分析.世界临床药物[J],2007,28(1)：44-46.
[8]铁步荣,乔旺忠,马忠明,等.人服用含雄黄中成药后尿中砷含量的动态研究[J].中国中药杂志,1992,17(5)：285-288.
[9]万丽,黄珍,赵力.等.牛黄解毒片中砷的体内吸收与分布——牛黄解毒片中雄黄的系统研究(Ⅱ)[J].时珍国医国药,2004,14(5)：257-258.
[10]张力,高思华,周超凡,等.从牛黄解毒丸(片)看含砷中成药的安全性问题[J].中国中药杂志,2006,31(23)
[11]姜泓,费思平,陈再兴,等.氢化物冷阱捕集原子荧光光度法测定人工胃液、水中牛黄解毒片可溶性砷的含量[J].中药材.2008.31(3)：450-452.
[12]傅丽玲,周宗灿.宫恩聪,等.牛黄解毒片经口对大鼠的急性和14天毒性[J].北京医科大学学报,1997,29(6)：546.
[13]张桥主编.卫生毒理学基础[M].北京：人民卫生山版社,2000,138.
[14]张天宝.当前遗传毒理学的研究动态[J].毒理学杂志,2007,21(5)：359-365.
[15]张春颖,周钟鸣.常见中药的致突变性研究进展[J].中国中医药信息杂志,2001,8(3)：20
[16]王钦茂.李莉,方华武,等.中药致癌、致突变和生殖毒性研究概况[J].安徽中医学院学报,2001,20(5)：64-67.
[17]王瑞,胡边,殷学军.中药遗传毒理学研究进展[J].中成药,2002,24(1)：57-59.
[18]孙耀光,李保兰.中医药抗诱变和抗突变作用[J].陕西中医学院学报,2005,28(5)：59-61.
[19]马哲,梁茂新.中药配伍减毒增效研究现状、问题与思考[J].辽宁中医药大学学报,2011,13(8)：187-190.
[20]李军生,路燕,邹义英.中药配伍减毒及其应用[J].中医杂志,51(增刊1)：43-45.
[21]郭盛.唐于平.宿树兰.近10年来中药配伍减毒的现代研究进展[J].中国实验方剂学杂志.2008,,14(10)：74-79.
[22]孟锐,孙建飞,唐冬蕾,等.中成药安全性评价研究现状及其基本对策的探讨[J].中医药信息,2005,22(6)
[23]New zealand medicines and medical devices safety authorityMediareleases 2003:Director-generals' privileged statement under section98 of themedicines act 1981-traditional Chinese medicine[N]·http:www medsafe·govtnz/hot/media/media2003·htm, 2003-01-21·
[24]Medicines and healthcare products regulation agency·Herbal safe-ty news:Niu Huang Jie Du Pian[N]·http: //www·mhra·gov·uk/home/idcplg?IdcService=SS GET PAGE&nodeId=664, 2003-01-17·
[25]Environment Health Criteria 18[S]:Arsenic WHO. Geneva,1981.
[26]白爱梅,李跃,范中学.砷对人体健康的危害[J].微量元素与健康,2007(01)
[27]地方性砷中毒防治手册.哈尔滨：中国疾病预防控制中心地方病控制中心,2005.7.
[28]田小藕.谈雄黄及其用量[J].中国中医药信息杂志,2006,13(9)
[29]孙恩亭,卜新柱.中药雄黄的致突变性实验研究[J].中国中医基础医学杂志,1998,4(11)：52.
[30]张天宝.新药遗传毒性评价方法的研究现状和发展趋势[J].癌变.畸变.突变,2002,14(4)：243-246.
[31]中华人民共和国国家标准,食品安全性毒理学评价程序和方法[S](GB15193-2003)
[32]Maron DM and Ames BN.Revised methods for the Salmonella mutagenicity test[J].Mutation Research 1983,113(2):173-215.
[33]中华人民共和国药政局,汇编.新药临床前研究指导原则(药学药理学毒理学)[M].1993,211-213
[34]刘国廉主编,细胞毒理学[M].第一版,北京：军事医学科学出版社出版,2001,196-211.
[35]Singh NP,McCoy MT,Tice RR,et al.A simple of technique for quantitation of low levels of DNA damage in individual cells[J].Exp Cell Res,1988,175:184-191.
[36]Mckelvey-Martin VJ,Green MH,Schmezer P, et al. The single cell gel electrophoresis assay (comet assay):a European review[J].Mutat Res,1993,288:47-63.
[37]朱文文,王晓涛,DNA损伤检测--单细胞凝胶电泳技术的研究[J].微量元素与健康研究,2007,24(3)：6-7.
[38]胡启之OECD新发布急性经口毒性试验方法简介[J].毒理学杂志,2005,
[39][ZH]GPT2-1,药物遗传毒性研究技术指导原则[S],国家食品药品监督管理局,国食药监注[2007]643号.
[40]Sasaki YF, Lzumiyama F,Nishidate E,et al.Detection of roden liver carcinogen genotoxicity by the alkaline single cell gel electrophoresis assay in multiple mouse organs(liver lung spleen kidey and bone marrow)[J].Mutat Res,1997,391:201-214
[41]刘嵘,濮德敏.雄黄的研究进展[J].时珍国医国药,2007,18(4)：982-984.
[42]岳旺,刘文虎,王兰芬,等.中国矿物药的急性毒性测定[J].中国中药杂志,1989.14(2)：42.
[43]康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察[J].时珍国医国药,1998,9(4)：322.
[44]李信民,陈思宇,王怀宇,等.瑞尔康主成分雄黄的动物急性毒性试验[J].现代中医,2001,1：43-44.
[45]仝燕,张英军,李先荣.湖南石门雄黄的研究[J].中国中医药科技,1997,4(5)：286.
[46]张伟,余伯阳,寇俊萍,等.雄黄活性物质的毒效相关性初步研究[J].中国天然药物,2004,2(2)：123-125.
[47]张亚敏,纪淑芳,蔡连之,等.雄黄生品与酸奶飞炮制品的毒理学比较[J].长春中医学院学报,2000,16(1)：46.
[48]范麒如,寇俊萍,张伟,等.天然雄黄与精制雄黄对小鼠肝脏损伤的初步研究[J].中国天然药物[J]，2007,5(1)：63-66.
[49]孙恩亭,卜新柱,钱怡宁,等.中药雄黄的致突变性实验研究[J].中国中医基础医学杂志,1998,4(11)：52.
[50]董菊,詹臻,王明艳.彗星试验检测雄黄对中国仓鼠肺细胞DNA的损伤作用[J].上海中医药杂志,2009,43(3)：79-81.
[51]汤毅珊,欧卫平,王宁生.等.雄黄单次或多次给药在大鼠体内的药代动力学和组织分布[J].中药药理与 临床,2009,25(3)：39-42.
[52]张娟,汤毅珊,刘启德.雄黄中砷的毒代动力学及组织学分布[J].中国中药杂志,2010,35(13)1750-1753.
[53]红缨,滕智平,陆道培,等.四硫化四砷对急性早幼粒细胞白血病细胞株NB4的凋亡作用[J].中国药理学与毒理学杂志,2002,16(1)：37.
[54]梁国刚.张启伟.朱砂、雄黄中各成分的溶解度对其药效、毒副作用的影响[J].中国中药杂志,2002,27(5)：391-392.
[55]叶祖光,王智民,王跃生,等.安宫牛黄丸中朱砂和雄黄的药理作用特点与安全性评价研究[J].医学研究通讯,2005.34(9)：35
[56]潘英伟,陈卫平,奚丽君.甘草减毒作用的应用与机理分析[J].南京中医药大学学报,2008,24(6)：428-430.
[57]邰昌松,王振宇,贾光,等.牛黄及制剂对正己烷致小鼠肝、肾脂质过氧化的保护作用研究[J],中国职业医学,2006,33(6)：417-419.
[58]傅乃武,刘朝阳,张如意.甘草黄酮体抗促癌、抗致突和抗氧化作用的研究[J].天然产物研究与开发,1995,7(4)：29-34.
[59]KITCHIN K T, AHMAD S. Oxidative stress as a possible mode of action for arsenic carcinogenesis[J]. Toxicol Lett,2003,137(122):3213.
[60]Li Z, An Y. Advance on oxidative stress mechanism of arsenic[J].Wei Sheng Yan Jiu, 2009,38(5):634-636.
[61]Hartmann A, Speit G. Comparative investigations of the genotoxic effects of metals in the single cells gel (SCG) assay and the sister chromatid exchange(SCE) test[J]. Environ Mol Mutagen,1994, 23 (4):299-305.
[62]Kligerma AD,Tennant AH.Insights into the carcinogenic mode of action of arsenic[J]. Toxicol Appl Pharmacol, 2007, 222(3):281-288.
[63]张志杰,周群,尉京志,等.我国药用雄黄的晶体结构鉴定[J].光谱学与光谱分析,2011,31(2)：291-296.
[64]国家药典委员会.中华人民共和国药典[S].二部.北京：化学工业出版社,2005：附录76.
[65]中华人民共和国国家标准,食品卫生检验方法理化部分(一).北京：中国标准出版社,2004.
[66]宋成岩.刘宇,朴锦花,等.黄芩抗氧化化学成分的研究[J].时珍国医国药,2007,18(4)：856-857.
[67]陶玉珍,刘毅,郭启明,等.大黄抗突变作用的研究[J].癌变·畸变·突变,1998,10(4)：41-243.
[68]姜泓,孟舒,陈再兴,等.氢化物发生冷阱捕集原子荧光光度法测定人工肠液、水中牛黄解毒片中可溶性砷的含量[J].中药材,2009.32(4)：629-631.
[69]刘海涛.AFS法在重金属元素分析中的应用及创新[J].食品安全导论,2010,(01)。
[70]白爱梅,李跃,范中学.砷对人体健康的危害.微量元素与健康研究[J].2007,24(1)：61-62。
[71]张景红,樊秦,李红玉.雄黄及微生物炮制液砷形态和毒性分析[J].中药材,2010,33(5)：684-688。
[72]盖秀兰.有毒微量元素砷的毒性研究[J].白城师范学院学报,2006,20(4)：36-38.
[73]李贞,安艳.砷毒性作用氧化应激机制研究进展[J].卫生研究,2009,38(5)：634-640.
[74]唐功.活性氧·抗氧化酶及抗氧化剂之间关系的探讨[J].安徽农业科技,2010,38(33)：18619-18621.
[75]孙鲜策,蔡竹,刘爽,等.GSH对砷氧化损伤保护作用的研究[J].大连医科大学学报,2008,30(6)：500-502
[76]徐敏.论人体的自由基和抗氧化剂-谷胱甘肽[J].中国医药导报,2006,3(2)：127.
[77]杨琳,廖明芳,季欣然,等.超氧化物岐化酶在医学领域的研究现状[J].现代生物医学进展,2010,10(2)：396-310.
[78]杨湘山,李景舜,吕焱,等.生姜提取物对X射线损伤小鼠肝脏脂质过氧化的影响[J].现代预防医学,2007,34(3)：436-437.
[79]洪莉,蔡威.凋亡与肝细胞损伤机制的研究进展[J].临床小儿外科杂志,2006,5(1)：42.
[80]刘文兰,张颖.细胞凋亡检测方法——TUNEL[J]解剖科学进展,1999,5(4)：330-332.
[81]陈春莲,蓝儒竹,叶章群,等TUNEL技术方法的探讨[J].同济医科大学学报,2001,30(3)：274-276
[82]]李晶媛,李树臣,杨维良TNF-a诱导肝细胞凋亡机制的回顾与展望[J].世界华人消化杂志,2007,15(6)：606.
[83]Ogretmen B,Safa A R.Down-regulation of apoptosis-related bcl-2 but notbcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breastcancer cells[J].Int J Cancer, 1996,67 (5):608.
[84]Brooks C, Dong Z.Regulation ofmitochondrialmorphological dy-namics during apoptosis by Bcl-2 family proteins:a key in Bak?[J].CellCycle,2007,6(24):3043-3047.
[1]张志杰,周群,尉京志,等.我国药用雄黄的晶体结构鉴定[J].光谱学与光谱分析,2011,31(2)：291-296.
[2]江苏新医学院主编.中药大词典[M].上海：上海人民出版社,1977：23-27.
[3]Medicines and healthcare products regulation agency-Herbal safe-ty news:Niu Huang Jie Du Pian.http:// www·mhra·gov·uk/home/idcplg IdcService= SS GET PAGE&nodeld= 664,2003-01-17.
[4]岳旺,刘文虎,王兰芬,等.中国矿物药的急性毒性测定[J].中国中药杂志,1989,14(2)：42.
[5]康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察[J].时珍国医国药,1998,9(4)：322.
[6]仝燕,张英军,李先荣.湖南石门雄黄的研究[J].中国中医药科技,1997,4(5)：286.
[7]李信民,陈思宇,王怀宇,等.瑞尔康主成分雄黄的动物急性毒性试验[J].现代中医,2001,1：43-44.
[8]张伟,余伯阳,寇俊萍,等.雄黄活性物质的毒效相关性初步研究[J].中国天然药物,2004,2(2)：123-125.
[9]张亚敏,纪淑芳,蔡连之,等.雄黄生品与酸奶飞炮制品的毒理学比较[J].长春中医学院学报,2000,16(1)：46.
[10]范麒如,寇俊萍,张伟,等.天然雄黄与精制雄黄对小鼠肝脏损伤的初步研究[J].中国天然药物[J],2007,5(])：63-66.
[11]孙恩亭,卜新柱,钱怡宁.等.中药雄黄的致突变性实验研究[J].中国中医基础医学杂志,1998,4(11)：52.
[12]董菊,詹臻,王明艳.彗星试验检测雄黄对中国仓鼠肺细胞DNA的损伤作用[J].上海中医药杂志,2009,43(3)：79-81.
[13]吴文斌,汤家铭,祝晓雯,等.中药雄黄对孕大鼠母体和胚胎-胎仔发育的毒性[J].毒理学杂志,2009,23(5)：380-383.
[14]叶祖光,王智民,王跃生.等.安宫牛黄丸中朱砂和雄黄的药理作用特点与安全性评价研究[J].医学研究通讯,2005,34(9)：35.
[15]汤毅珊,欧卫平,王宁生,等.雄黄单次或多次给药在大鼠体内的药代动力学和组织分布[J].中药药理与临床,2009,25(3)：39-42.
[16]张娟,汤毅珊,刘启德.雄黄中砷的毒代动力学及组织学分布[J].中国中药杂志.2010,35(13)：1750-1753.
[17]张力,高思华,周超凡,等.从牛黄解毒丸(片)看含砷中成药的安全性问题[J].中国中药杂志.2006,31(23)
[18]傅丽玲,周宗灿,宫恩聪,等.牛黄解毒片经口对大鼠的急性和14天毒性[.J].北京医科大学学报,1997,,29(6)：546.
[19]董菊,唐萌,王姝.牛黄解毒片的遗传毒性研究[J].癌变.畸变.突变,2009.21(6)：477-478.
[20]万丽,黄珍,赵力.牛黄解毒片中砷的体内吸收与分布—牛黄解毒片中雄黄的系统研究[J].时珍国医国药,2003,14(5)：257-258.
[21]林飞,宋谊萍.中药清心丸的遗传毒性研究[J].癌变.畸变.突变,1995,7(5)：280.
[22]林飞,宋谊萍.中药清心丸的致畸毒性研究[J].癌变.畸变.突变,1995,7(4)：243.
[23]Liu J, Liang SX,Lu YF. Realgar and realgar-containing Liu-Shen-Wan are less acutely toxic than arsenite and arsenate. J Ethnopharmacol,2011 Mar 8; 134(1):26-31. Epub 2010 Dec 1.
[24]齐卫红,李欣,沈连忠,等.Beagle犬经口给予六神丸急性毒性研究[J].毒理学杂志,2007,21(4)：303.
[25]齐卫红,沈连忠,李欣,等Beagle犬重复给予六神丸28 d及恢复期14 d毒性研究[J].毒理学杂志2007,21(4)：304.
[26]Lu YF, Yan JW, Wu Q, et al. Realgar and cinnabar con taining An Gong Niu Huang Wan(AGNH) is much 1 ess acutely tox ic th an sodium arsenite and mercuric chloride [J]. Chem Biol Interact, 2011, 189(12):134-140.
[27]Lu YF, Wu Q, Yan JW, et al. Realgar, cinnabar and An Gong Niu Huang Wan are much less chronically nephrotoxic than common arsenicals and mercurial [J]. Exp Biol Med(May wood),2011,236(2):233-239.
[1]Ostling O, Johanson K J.Microelectrophoretic study of radiation2induced DNA damages in individual mam Malian cells[J].Bioehem Biophys Res Commun,1984, (123):37-40.
[2]Singh N P,Stephens R E.Micro gel electrophoresis:Sensitivity, mechanisms, and DNA electrostretching [J].MutRes,1997,(383):167-175.
[3]田云,卢向阳,易克,等.单细胞凝胶电泳技术[J].生命的化学,2004,24(1)：77-78.
[4]朱文文,王晓涛.DNA损伤检测--单细胞凝胶电泳技术的研究[J].微量元素与健康研究,2007,24(3)：6-7.
[5]李彦,谢明.单细胞凝胶电泳技术操作方法介绍[J].生物学通报,2005,40(7)：50--53.
[6]江励华.中药抗DNA损伤作用的研究[J].医药导报,2004,23(4)：250-252.
[7]杨敏.仙草提取物对小鼠脾淋巴细胞DNA氧化损伤保护作用的研究[J].浙江大学学报(医学版),2006,35(1)：35-38.
[8]路萍,赖炳森,李植峰,等.白黎芦醇体外抗氧化活性和对细胞DNA损伤防护作用的实验研究[J].中医药学报,2004,32(1)：50-52.
[9]路萍,赖炳森,梁萍,等.姜油体外抗氧化活性和对细胞DNA损伤防护作用的实验研究[J].中国中药杂志,2003,28(9)：873-875.
[10]王晖,张杰,张淑华,等.甜杏仁对H2O2诱导大鼠外周淋巴细胞DNA损伤的影响[J].首都医科大学学报,2007,28(5)：609-612.
[11]王洪侠.桑叶及桑白皮对老龄小鼠脾细胞DNA氧化损伤影响[J].赤峰学院学报,2007,23(3)：77-79.
[12]马庆华,张鹏霞,郭红艳,等.白术多糖对D_半乳糖致衰大鼠神经细胞抗氧化作用研究[J].中国老年学杂志,2006,12(26)：1658--1659.
[13]张慧丹,孙洁,欧芹,等.衰老HDF细胞DNA损伤与HSP70 mRNA表达及山茱萸多糖的作用[J].中国老年学杂志,2009,29(16)：2007-2009.
[14]陈刚,毛珺.脾肾双补法对衰老小鼠胸腺细胞DNA氧化损伤修复的影响[J].中国现代医生,2007,45(13)：90-91.
[15]王瑞,胡边,殷学军.中药遗传毒理学研究进展[J].中成药,2002,24(1)：57-59.
[16]王小红,夏明珠,龙文,等.黄芩的致突变性研究[J].新中医,2000,2(10)：30-31.
[17]王小红,江洪,夏明珠,等.姜半夏致突变性实验研究[J].江苏中医药,2002,23(8)：42-43.
[18]周东升,袁慧.杜仲提取物对小鼠淋巴细胞DNA损伤的研究[J].中曾医学杂志,2005,5：11-13.
[19]王金勇,王亚其,张建军,等.鸟头类中药对CHL细胞的DNA损伤作用[J].现代预防医学,2007,34(7)：1204-1206.
[20]肖立峰,张天虹,刘江涛,等.中药薏苡仁酯作用喉癌Hep_2细胞的体外研究[J].哈尔滨医科大学学报,2004,38(3)：252-253.
[21]魏雪涛,蒋建军,吴涛,等.姜黄素拮抗亚砷酸钠所致的DNA链断裂损伤[J].药学学报,2002,37(11)：833-836.
[22]周敏,周慧.姜黄素对长波紫外线所致DNA损伤的拈抗作用[J].山西医药杂志,2004.33(12)：1031-1033.
[23]曹军,姜丽华,耿成燕,等.姜黄素对丙烯酰胺致HepG2细胞DNA损伤的保护作用[J].卫生研究,2009,38(16)：392-394.
[24]黄炜,陈新美,张志凌,等.18_甘草次酸诱导人乳腺癌细胞凋亡及其细胞内Ca2+水平的变化[J].中国癌症杂志.2006,16(2)：102-106.
[25]陈新美,黄炜,张志凌,等.甘草酸诱导人乳腺癌细胞凋亡和细胞内Ca2+的相关性研究[J].中国现代医学杂志,2006,16(24)：3729-3732.
[26]王春玲,傅攀峰,李宏伟,等.葛根素对血管内皮细胞DNA损伤的保护作用[J].中国微循环,2004,8(6)：361-364.
[27]刘鹏,曹魏,岳志军,等.中药复方“益糖康”抗糖尿病大鼠DNA损伤的实验研究[J].中国中医基础医学杂志,2002,8(10)：15-16.
[28]李瑛,刘志红,郭啸华,等.马兜铃酸Ⅰ致肾小管上皮细胞DNA损伤的实验研究[J].肾脏病与透析肾移植杂志,2004,13(1)：7-11.
[29]王大方,高广,杨静玉,等.正交设计法研究麻黄汤对小鼠外周血淋巴细胞DNA的损伤作用[J].中药药理与临床,2006,22(3,4)：7-9.
[1]王冬娜.中药对恶性肿瘤化疗减毒作用的研究进展[J].时珍国医国药,2008,19(1)：242-243.
[2]阴健,郭力弓.中药现代研究与临床应用[M].北京：学苑出版社,1993：5922605.[3]中华人民共和国卫生部医政司编.中国常见恶性肿瘤诊治规范(第九分册)[M].北京,北京医科大学,
中国协和医科大学联合出版社,1992：9-15.
[4]孙燕,周际昌.临床肿瘤内科手册[M].第四版,北京,人民卫生出版社,2003：106-107.
[5]李廷谦,李幼平,王刚.中西医结合循证医学[M].第1版,上海,上海科学技术出版社,2006：318.
[6]段萍,王再漠,黄芪在恶性肿瘤的化疗中的增效减毒作用的临床研究[J].中国中西医结合杂志,2002,22(7)：515-517.
[7]甘宁,陈焕朝.黄芪注射液辅助化疗治疗老年肺癌的疗效观察[J].肿瘤防治研究,2004,3(7)：433-434.
[8]唐黎,武明花.黄芪注射液联合化疗治疗恶性肿瘤临床观察[J].中国医师杂志,2006,8(3)：425-426.
[9]万丽娜,冯刚.黄芪注射液联合化疗治疗恶性肿瘤的临床研究[J].中国药房,2009,20(9)：703-705.
[10]王和融,檀朝甲.黄芪注射液对肿瘤患者化疗的减毒作用[J].中国中医药科技,2005,12(6)：407-408.
[11]张春霞.黄芪注射液对中晚期非小细胞肺癌化疗后骨髓系统的影响[J].海南医学学报,2007,13(5)：437-438.
[12]邹雨荷,刘雪梅.黄芪注射液配合化疗对晚期非小细胞肺癌患者生存质量的影响[J].中国中西医结合杂志.2003.10.23(10)：733-735
[13]杜现华,桂心佳,张克信等.黄芪注射液配合化疗治疗恶性肿瘤临床观察[J].上海医药,2000,21(2)：16-18.
[14]王红,王莉,雷秋模.大剂量黄芪注射液联合化疗治疗恶性肿瘤临床观察[J].江西中医药,2006,12,37(288)：43-44.
[15]潘峰.黄芪注射液辅助化疗增效减毒临床研究[J].山东中医药大学学报,2003,3,27(2)：137-139.
[16]蔡丰穗,王在国.黄芪注射液联合化疗在治疗恶性肿瘤中的应用[J].中医中药,2009,7,6(19)：130-131.
[17]李艳丽.黄芪注射液联合化疗治疗恶性肿瘤临床观察[J].中华实用中西医杂志,2002,2(15)：1348-1349.
[18]许红娟,陈敏珠.黄芪多糖的抑瘤作用及其机制[J].中国医院药学杂志,2005,25(10)：923-925.
[19]刘莎,符州.黄芪的免疫调节作用及临床应用[.J].国际中医中药杂志.2006,28(4)：203-205.
[20]解庆东,赵慧男.黄芪抗肿瘤机制研究与临床应用[J].医药导报,2003,22(2)：109-110.
[21]Suresh R, Chandra P. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions[J].The Oncologist.2008,3(suppl 1):5-12
[22]D'Addario G, Pintilie M, Leighl NB,et al.Platinum-based versus nonplatinum-based chemotherapy in advanced non-small-cell lung cancer:a meta-analysis of the published literature[J].J Clin Oncol,2005,23(13): 2926-2936
[23]陆益,陆益线.参芪扶正注射液的药理作用和临床应用[.J].时珍国医国药,2006,17(10)：2083-2085.
[24]Higgins J. Green S (eds). Cochrane handbook for systematic reviews of interventions 4.2.6. In The Cochrane library,301 Issue 4. Wiley:Chichester (updated September 2006),2006.
[25]WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Orgnaization,1979
[26]全国肿瘤防治办公室等合编.中国常见恶性肿瘤诊治规范(原发性支气管肺癌).北京：北京医科大学、中国协和医科大学联合出版社,1990：1-19.
[27]Yates JW, Chalmer B, McKegney FP:Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer, 1980,45:2220-2224
[28]Guyatt GH, Sackett DL, Cook DJ. Users' guides to the 309 medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working GroupJAMA,1993,270:2598-2601
[29]郝秀丽,吕晓君.参芪扶正注射液对晚期非小细胞肺癌化疗患者生存质量的影响[J].实用肿瘤学杂志,2008,22(5)：458-459
[30]王昆,覃建雄,农云.参芪扶正注射液联合NP化疗方案治疗晚期非小细胞肺癌临床观察[J].现代中西医结合杂志,2007,16(26)：3797-3798
[31]康桂艳,李波.参茂扶正注射液联合化疗治疗晚期非小细胞肺癌36例[J].中国中西医结合杂志,2006,26(6)：565-566
[12]龚志敏,王言,余川运,等.参芪扶正注射液配合NP方案化疗治疗老年晚期非小细胞肺癌疗效观察[J].中国中医药信息杂志,2008,15(9)：64-65
[33]汪秀云,黄宗琼,李虹,等.参芪扶正注射液辅助NP方案治疗老年晚期非小细胞肺癌的观察及护理[J].中国肺癌杂志,2007,10(3)：234-236
[34]王玉洲,杨志雄,廖思海,等.参芪扶正注射液联合国产长春瑞滨+卡铂方案治疗晚期非小细胞肺癌临床观察[J].临床内科杂志,2007,24(3)：206-207
[35]李铁文,向丽,童方友,等。参芪扶正注射液联合化疗治疗晚期肺癌临床观察[J].现代生物医学进展,2009,9(10)：1917-1919
[3]李勇,陈思现,黄瑞文.参芪扶正注射液配合NP方案治疗晚期非小细胞肺癌的临床观察[J].中国现代医药杂志,2007,9(3)：40-41
[37]吕靖.参芪扶正注射液辅助化疗治疗晚期非小细胞肺癌临床观察[J].中国医药导,2008,5(36)：73-74
[38]赵作银,吴德林,陈猛,等.参芪扶正注射液辅助NP方案治疗老年晚期非小细胞肺癌近期疗效[J].现代肿瘤医学,2007,15(1)：42-43
[39]耿丽.参芪扶正注射液联合化疗治疗非小细胞肺癌[J].医药论坛杂志.2004.25(17)：29-30
[40]于清忠.参芪扶正注射液联合化疗治疗中晚期非小细胞肺癌[J].中国中西医结合杂志.2007.27(5)：473-474
[41]刘城林,陈为平,崔书中,等.参芪扶正注射液辅助化疗治疗老年非小细胞肺癌临床观察[J].中国中医结合杂志,2004,24(10)：901-903.
[42]刘鹏辉,廖国清,王红酶.参芪扶正注射液配合化疗治疗晚期肺癌的近期疗效[J].第三军医大学学报,2007,29(3)：259-260.
[43]潘彦康,黄敏,区梅.参芪扶正注射液辅助化疗治疗非小细胞肺癌临床观察[J].中国临床医生杂志,2008,3(4)：43-45.
[44]郑加辉,陈有法.参芪扶正注射液联合NP方案治疗晚期非小细胞肺癌42例[J].江西中医药,2009,40(6)：58-59.
[45]邹彦,柏玉举,阮培刚.参芪扶正注射液联合紫杉醇加卡铂治疗晚期非小细胞肺癌临床观察[J].实用肿瘤杂志,2005,20(3)：260-262.
[46]罗世政,龙金华,余祥艳.参芪扶正注射液联合紫杉醇加顺铂治疗晚期非小细胞肺癌的临床观察[J].肿瘤研究与临床,2006,18(3)：181-183.
[47]罗社文,黄燕苹,陕海丽,等.参芪扶正注射液联合紫杉醇加顺铂治疗中晚期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2007,12(5)：381-38.
[48]张福林.参芪扶正注射液配合紫杉醇加顺铂治疗中晚期非小细胞肺癌的临床观察[J].现代肿瘤医学,2008,16(7)：1165-1166.
[49]赵艳勋,王春雨,李静,等.参芪扶正注射液联合TP方案治疗非小细胞肺癌疗效观察[J].中国误诊学杂志.2009,19(21)：5129-5130.
[50]于飞,李凯.参芪扶正注射液辅助化疗治疗非小细胞肺癌临床观察[J].中国中西医结合杂志,2007,21(2)：166-167.
[51]何文杰,赵金奇.参芪扶正注射液联合吉西他滨加顺铂方案治疗晚期非小细胞肺癌的临床观察[J].中国肿瘤学进展,2008,6(4)：432-434.
[52]Michael Borens t ein, L. V. Hedges, J. P. T. Higgins, et al. Introduction to Meta-Analysis. Rothstein (?) John Wiley & Sons, Ltd.2009
[53]薄芯,董历平,屠蘅菁,等.黄精、党参和绿茶减轻环磷酰胺毒副作用初探[J].中医研究,1997,10：20-22.
[54]王润田,单保恩,李巧霞,等.黄芪提取物免疫调节活性的体外实验研究[J].中国中西医结合杂志,2002,2：453-455.